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ABSTRACT
Following traumatic brain injury (TBI) and stroke, secondary injury cascades can
lead to axonal damage and persistent microglia activation, respectively, in subcortical
regions of mice. Current techniques, such as diffusion tensor imaging (DTI) and
histology are used to observe features related to damage, but DTI lacks cellular resolution
and histology is conducted on fixed tissue, preventing longitudinal studies in the same
mouse. The combination of cranial windows and multiphoton microscopy (MPM) is used
to image cells in the upper layers of the mouse cortex, but resolution rapidly degrades
with imaging depth, making it difficult to observe white matter and subcortical regions
following TBI and stroke. To circumvent this challenge, a novel imaging system was
developed capable of obtaining longitudinal data related to this secondary damage in
subcortical regions of mice.
An existing technology, gradient refractive index (GRIN) lenses, was used in
conjunction with MPM to image mice before and after injury models. GRIN lenses were
attached to low profile head plates and surgically implanted into the brain of mice to
acquire time-lapse images of white matter for 60 days following midline fluid percussion
injury and microglia 24 hours after a MCAo stroke model. Thy1-YFP and Cx3cr1tdTomato mice were used to compare changes in white matter fiber tracks and microglia
dynamics, respectively. In a model of stroke, injured mice exhibited larger soma areas as
compared to control treated animals, demonstrating their activated morphology. When
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the potential therapeutic, Annexin A1, was administered, treated animals had smaller
soma areas as compared to the saline treated animals, signifying Annexin A1’s potential
to mitigate inflammation. The system was also used in a model of TBI and the results
indicated injured animals developed significantly more varicosities and terminal bulbs
than uninjured animals. When minocycline, an FDA approved antibiotic, was
administered, treated animals had fewer varicosities and terminal bulb development,
demonstrating the potential of the therapeutic to protect against axonal degeneration
following TBI. Overall, the imaging system was successfully used in preclinical trials to
demonstrate the effectiveness of two potential therapeutics in two brain injury models.
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Figure 31. TRIO Platform: an in vivo integrated imaging support system. (A) TRIO
Platform with gas anesthesia supplied by a compact, portable gas anesthesia system
(SomnoSuite®, Kent Scientific Corp.). Isoflurane is supplied from a syringe (white
arrow). The integrated digital vaporizer (yellow arrow) is much smaller than
traditional vaporizers which markedly reduces the amount of anesthesia used for
surgeries and for imaging sessions. (B) Anesthetized mouse positioned and warmed
for imaging using the TRIO Platform on the stage of a multiphoton microscope. The
overall height of the base plate with circulating warm water and the mouse head is
only 20 mm. This relatively small height will enable its use on a wider range of
microscopes. (The white paper towels around the platform were used to block
reflections from the lights used for this photo. They are not required for imaging.)
The compact anesthesia system can be placed to the side of the stage within the
microscope enclosure or outside of the enclosure [15].
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Figure 32. Integrated system with the top cover of the base plate removed to show
the serpentine water channel. Parts were 3D printed and designed in SolidWorks®.
Dimensions are in mm [15].
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Figure 33. Components of TRIO Platform. A. This view shows features of the base
plate that cannot be seen in Figure 32, such as the extensions of the base plate for
attaching the head plate holder posts (arrowheads) and the slotted tongue (arrow)
for attaching the nose cone. (B-C) Two views of nose cone design. Channel under
nose cone in (B, arrow) sides into a slot in the tongue (A, arrow). D. Gas inlet (right
side) and outlet (left side) are integrated into one piece that attaches to the tubular
component of the nose cone (C, arrow). Dimensions are in mm [15].
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Figure 34. TRIO Platform 3D-printed system. (A) Assembled system with tube
fittings for attachment to inlet (Iw) and outlet (Ow) water lines and Luer lock fittings
for attachment of inlet (Ig) and outlet (Og) tubes from a gas anesthesia system. The
elastomeric shroud is held onto the nose cone with plastic tape from the underside of
the device (black arrow). (B) Head plate holder posts and machine screws. Two
screws are placed in holes in the base plate and screwed into tapped holes in the posts
(black arrows) to attach the posts to the base plate. A square hole in the post holds an
arm of the head plate holder (black arrowhead) and a round taped hole in the post
(white arrowhead) holds a set screw (C) to secure the position of the arm in the
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square hole. (C) Head plate holders with the accompanying screws that secure the
head plate holders to the holder posts [15].
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permanently attached to the skull of a mouse. Head plate holder posts position the
holders and head plate above the base plate with sufficient space for positioning the
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head plate is held by a 3D printed head plate grips that are attached to the end of a
standard probe holder for a stereotaxic device. (A) Probe holder with custom grips
attached. (B) View showing details of grips. (C) Grips in use during surgery to attach
a head plate. The cut-out in the head plate around the craniotomy provides room to
attach an injury hub for a fluid percussion injury, however, a glass cover slip can be
attached to this area for use as a cranial window, or it can be used for applying
additional adhesive, if desired. For our experiments, a GRIN lens is attached to a
round glass cover slip that is glued under the opening that is just rostral and to the left
of the craniotomy. The lens is lowered into a separate craniotomy (not visible in this
photo) as the head plate is lowered. [15]
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Figure 38. Height comparison. Comparison of the size of the TRIO platform with a
Mouse and Neonatal Rat Adaptor with an electrically heated warming pad. (A)
Anesthetized mice restrained in the two systems. The TRIO system is capable of
warming the entire mouse, but is still much smaller than the Mouse and Neonatal Rat
Adaptor. (B) Close-up image of the two restraint systems. The top of the mouse head
in the TRIO system is 2.2 cm above the table compared to 7.0 cm in the other system
[15].
48

17

Figure 39. In vivo image set of astrocytes in lower levels of cortex viewed through an
implanted GRIN lens. A z-stack of 51 images spaced 1 m apart in depth was
acquired through a GRIN lens implanted in an adult GFAP-GFP mouse. Astrocyte
cell bodies and processes were observed throughout the volume. Z-projections were
made of several consecutive image planes (steps). All images were projections of 5
consecutive image planes with the exception of Image E in which 10 planes were
used for the projection. The most dorsal image plane was defined as plane 1 and the
most ventral image was plane 51. Z-projection planes for A-H were, as follows: A. 15, B. 5-10, C. 10-15, D. 15-20, E. 25-35, F. 35-40, G. 40-45, H. 45-50. A Gaussian
filter with σ=1.33 was applied to all channels to reduce background noise. Scale bar
= 5 µm [15].
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Figure 310. Two-channel in vivo image obtained through an implanted GRIN lens.
The image is from prefrontal cortex of an adult GFAP-GFP mouse implanted with a
350 m diameter GRIN lens. Texas red-dextran dye was injected into the tail vein to
visualize the vasculature. A few glial cells expressing GFP under the GFAP promoter
can be seen near one of the blood vessels near the center of the image. A Gaussian
filter with σ=1.33 was applied to all channels to reduce background noise. Scale bar
= 5 m [15].
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Figure 41. Nissl stained sagittal section (image, exclusive of locations for analyzing
microglia activation levels, courtesy of Dr. Xiao Hong Lu, Louisiana State University
Health Sciences Center, Shreveport, LA). Locations for analysis of microglia
activation state in brain slice images were, as follows (A) CA3 in the hippocampus,
(B) the cerebral cortex directly above CA3, (C) the necrotic core of the ischemic
region, (D) the transition zone, directly above position C on the ventral side of the
corpus callosum, (E) penumbra of the stroke, and (F) the rostral cortex.
60
Figure 42. Representative images at baseline and 24 hours after sham or transient (60
min) MCAo procedure. Insets are single cells showing activation states. Microglia
become activated (retracted processes) (B) as compared to both baseline (A, C) and
sham treated animal (D). Insets are representative images of microglia morphology.
Images are z-projections of 10 x 1 µm slices. Scale bar = 10 µm.
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Figure 43. AnxA1 may be protective against microglial activation, but not through
FPR2/ALX mechanism. Mice underwent sham (n=1) or transient (60 min) MCAo (n
= 8) and administered saline (n=2), AnxA1 (n=3) or AnxA1 + Boc 2 (n=2). Cell
soma area was calculated at baseline and at 24 hours post reperfusion. Data is
represented as mean normalized soma area ± SEM.
Figure 44. Representative brain slice images of positions B, E, and F comparing
microglia activation when treated with AnxA1 (A-C) versus treated with saline (DF). AnxA1 treated animals had microglia with smaller soma areas in the cortex after
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MCAo. Insets are representative, enlarged images of microglia morphology. Scale
bar = 15 µm.
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Figure 45. AnxA1 potentially has protective effects in the cortex. At 24 hours post
I/R, AnxA1 treated mice tended to demonstrate modulated inflammation, indicative
by smaller soma areas as compared to saline treated animals, but not through the
FPR2/ALX mechanism as the antagonist, Boc2, did not appear to be effective.
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Figure 46. Representative brain slice images from position A (hippocampus)
comparing microglia activation when treated with AnxA1 (A) versus treated with
saline (B).Insets are representative up close images of microglia morphology. Scale
bar = 15 µm.
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Figure 47. AnxA1 does not exhibit protective properties in the hippocampal region.
Saline and AnxA1 treated animals exhibited comparable cell soma areas.
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Figure 48. Representative brain slice images of position C (A, C) and position D (B,
D), the necrotic core and transition zone, respectively. Cell soma areas in the AnxA1
treated animals exhibited cells with resting morphology. Insets are representative
images of microglia morphology. Scale bar = 15 µm.
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Figure 49. AnxA1 modulates microglial activation in the ischemic core (position C)
and transition zone (position D). Treated animals exhibited smaller soma areas in
both positions. The antagonist, Boc2, was not effective in these regions and time
point.
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Figure 51. A GRIN lens (gray rectangle) is implanted just above the external
capsule (red circle) in order to image axonal damage over time. Adapted from
Paxinos and Franklin, 2012.
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Figure 52. Experimental Timeline.
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Figure 53. GRIN lens fabrication. Each implantable lens has 600 µm x 500 µm glass
window and a 1.7 mm long GRIN lens glued to a #1.5 3 mm in diameter glass
window. These lenses were affixed to a 1 mm thick stainless steel washer.
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Figure 54. Head plate construction was adapted to allow access to the craniectomy
(A) in order to attach the injury hub during the fluid percussion injury surgery (B).
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Figure 55. Injury hub attachment required the use of both Kwik-Sil, to cover and
protect the GRIN lens, and dental cement, to ensure proper pressure for the FPI
procedure.
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Figure 56. Fluid percussion injury device. The animal is connected to the device via
tube with a leur lock ending (A) and a hammer head (B) on a pendulum (C) hits the
fluid filled cylinder (D) which causes a brief pressure pulse (< 20 ms) onto the intact
dura of the mouse brain.
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Figure 57. Latency to fall times were normalized with baseline to reduce inter-animal
variability. The TBI-45 minute minocycline treated group did not have motor deficits
at any time point. Both TBI-vehicle and TBI-72-hr minocycline treated animals had
significant motor deficits at Day 2 and continued to exhibit deficits at Day 5 and Day
7 as compared to sham-vehicle treated animals. Data represented as mean ± SEM. * p
< 0.05 vs sham-vehicle at each time point
94
Figure 58. Undulations result from mechanical stretching and elongation of axons.
All injured groups exhibited more undulations than the sham injured group (A). Some
undulations persisted until Day 7, but by Day 14, no undulations were apparent in any
of the injured groups. Representative images of undulated axons (white arrows)
persisting until day 3 (B). Each image is a z projection of 11 x 1 µm slices. Scale bar
= 10 µm.
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Figure 59. Varicosities develop due to interrupted axonal transport after injury (white
arrows) (B). The TBI-vehicle treated group developed more varicosities over time
versus the sham injured and minocycline treated groups. When minocycline is
administered beginning at 45 minutes, it exhibits a protective effect by preventing
development of varicosities during the first week and is not significantly different
than the sham-vehicle at any time point. Administering minocycline beginning at 72
hours also protects against the development of future varicosities, apparent at day 14
(p = 0.07 versus TBI-vehicle) (A). * p < 0.05 (versus sham-vehicle), # p <0.05
(versus TBI-vehicle). Each image is a z projection of 11 x 1 µm slices. Scale bar =
10 µm (B).
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Figure 510. Terminal bulbs develop when an axon disconnects, eventually leading to
axon loss. (A, B) TBI-vehicle treated had the most persistent axonal bulbs and axonal
loss overtime. The TBI-45-min treated minocycline group had few terminal bulbs
and minimal axonal loss, with no development until day 14. (C-E) Representative
images of terminal bulbs (white arrows). Each image is a z projection of 11 x 1 µm
slices. Scale bar = 10 µm.
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Figure 511. Undulated axons can been seen at 1 hour (white arrows) and A) develop
into varicosities (white arrows) or B) recover over time (white arrows). Each image
is a z projection of 11 x 1 µm slices. A) Scale bar = 5 µm, B) Scale bar = 10 µm.
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Figure 512. Representative images demonstrating the difference in recovered
varicosities (solid, white arrow) or unresolved varicosities (dashed, white arrow).
Each image is a z projection of 11 x 1 µm slices from identical field of views. Scale
bar = 10 µm.
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Figure 513. Representative image of axon disappearing (white arrow) without the
formation of varicosities. It is possible the axon was damaged in an area outside the
field of view or the development of a terminal bulb was not identified at the imaging
time point. Each image is a z projection of 11 x 1 µm slices. Scale bar = 10 µm.
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Figure 514. Representative images demonstrating progressive axonal damage for
each of the treatment groups. Overall, less damage is apparent in the sham-sham (AF) and groups treated with minocycline at 45 minute (M-R) and 72 hours (S-X).
Individual axons with varicosities (white arrow heads) could be tracked over time to
determine their fate and time point at which they appear and recover. Scale bar = 10
µm.
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Figure 515. No statistical significant difference was measured between injured and
uninjured groups. All animals spent comparable time in the peripheral zones of the
arena.
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Figure 516. There was no statistical difference between injured or uninjured groups
in the tail suspension test. However, it appears the TBI-72 hr minocycline treated
group spent the most time actively attempting to escape.
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Figure 517. Novel object recognition scores indicate that the TBI-vehicle and TBI72-hr minocycline treated animals were unable to discern between familiar and novel
objects, indicating a memory deficit is present. Both the sham-vehicle and TBI-45min minocycline treated spent significantly more time with the novel objects as
compared to the familiar objects, indicating administration of minocycline at 45
minutes post TBI is protective against the development of memory deficits. * p <
0.05 vs. familiar object
110
Figure 61. Representative time course images of in vivo diffusion of DiR-PgP with
10x objective. DiR-PgP spreads outward over the 72 hour time period (A-E).
Polyplexes appear to congregate around the vasculature (F). Each image is a z
projection of 11 x 1 µm slices. Scale bars: 100 µm (A-F)
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Figure 62. Representative images of DiR-PgP polyplex spread over a 2 mm in
diameter craniectomy. Images are pseudo colored with the look up table “Jet” in
ImageJ. DiR-PgP spreads outward beginning at 1 hour and continues to spread until it
covers the field of view at 72 hours post injection (A-E). Each image is a z projection
of 11 x 1 µm slices. Scale bar = 250 µm.
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CHAPTER 1
INTRODUCTION
1.1
1.1.1

Background

In Vivo Microscopy
In vivo studies are studies done in whole living organisms and in vivo imaging

uses a variety of modalities to conduct research at the organ, tissue, cell and molecular
level in animals, with murine models being especially popular. Imaging is crucial to
better understand the diseases, injury, and inflammation of the brain as well as being vital
in drug development. Furthermore, it is increasingly important to be able to image
animals longitudinally to better understand the progression of disease and injury and
understand the long-term effects of potential therapeutics.
The brain is a highly dynamic, complex structure, capable of gathering,
organizing, and responding to multiple inputs. One of the main challenges in
neuroscience is understanding the underlying mechanisms involved in brain function, as
well as its response to stimulus and injury. Brain function involves both temporal and
spatial properties, making it difficult to fully understand its capabilities. Current
modalities such as diffusion tensor imaging and magnetic resonance imaging allow the
collection of longitudinal data, but they lack the resolution required to understand the
brain at a cellular level. Histology and clearing methods provide cellular resolution, but
since these methods cannot be employed in living animals, temporal data cannot be
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collected. In vivo microscopy, specifically multiphoton microscopy, combined with novel
technologies offers an opportunity to collect both spatial and temporal data in both the
progression of brain injury and development of potential therapeutics.
1.1.2

Traumatic Brain Injury
Traumatic brain injury (TBI) is of great interest to biomedical researchers. Each

year, 1.1 million Americans are treated for a traumatic brain injury in an emergency room
setting, with approximately 50,000 injuries resulting in deaths [1]. An estimated 124,000
individuals discharged from the hospital with moderate to severe TBI develop long term
disabilities each year [2], with an estimated 3.32 million individuals currently living with
disabilities [3]. While individuals may survive a TBI, they often have limitations to their
daily living such as social integration and financial independence. Sixty-six percent of
individuals with a history of TBI will receive welfare or disability checks [4]. With TBI
affecting such a large population and many being of a young age, the occurrence carries
vast direct and indirect costs, $9.2 billion and $51.2 billion, respectively [5].
Traumatic brain injury is defined as damage to the brain as result of external
forces. These forces can include acceleration or deceleration, impact, crushing forces, or
penetration by an object. When this damage occurs, cognition and physical functions
become impaired. Additionally, social functions are affected, often resulting in
depression and anxiety [6]. Any type of laceration or penetration results in focal brain
damage, while acceleration forces cause diffuse brain damage. Focal contusions will
affect the gray matter of the brain, which constitutes the cell bodies while diffuse injuries
play a part in white matter or axonal damage [7]. Traumatic brain injury is a complex
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neurodegenerative condition, and its deleterious and progressive effects must be
understood if an effective therapeutic treatment is to be found.
1.1.3

Stroke
Ischemic stroke is a neurological deficit occurring from decreased blood flow to

the brain. Strokes cost the United States $34 billion annually and they kill approximately
130,000 people each year [8]. The American Heart Association (AHA) recognizes three
types of stroke, ischemia, hemorrhagic, and transient ischemic attack, with ischemia
accounting for an estimated 87 percent of all cases [9]. While ischemic stroke has a high
rate of prevalence, few therapies or strategies exist to treat stroke or to prevent secondary
damage. Despite the ongoing research in animal models of stroke, little has been done to
translate experimental studies to a clinical level. Currently, the only treatment available
for stroke is tissue plasminogen activator (tPA), which is a protein aiding in the
breakdown of clots. While this protein has been beneficial, it must be administered within
6 hours following the ischemic event, and has only been effective in approximately 5% of
all cases[10], [11]. Therefore, it is crucial we develop tools which can collect
longitudinal data to better understand the progression of the disease and how therapeutics
could intervene.
1.2

Project Overview

Discovering and optimizing therapies to aid in the recovery of traumatic brain
injury (TBI) and ischemic stroke is of great interest to the translational, biomedical
research community. Mice are often used in preclinical trials to test the effects of
candidate therapies. The research projects described in Chapters 4 and 5 were run as
preclinical trials implementing a novel, longitudinal imaging approach using mice.
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Following ischemia, microglia become activated, contributing to the expansion of the
infarct and mediating further damage [12]. An in vivo imaging system was tested to
demonstrate its ability to elucidate neuroinflammation and determine the efficacy of a
potential therapy, Annexin A1.
Current imaging modalities have shown that traumatic brain injury can cause
diffuse axonal damage, which is not caused by merely one event, but by a progression of
mechanical and cellular damage [13]. In addition, affected individuals have deficits in
functionality such as memory and learning. This research characterizes these cellular
changes over several weeks post-TBI. It uses multiphoton microscopy and implanted
gradient refractive index (GRIN) lens technology to image axonal damage in the external
capsule of mice. The external capsule is a region of the brain containing myelinated
axons, or white matter. An imaging system that was previously developed in the Murray
lab was modified in order to facilitate the induction of a TBI and collect high quality
images [14], [15]. Behavioral performance was compared for the same mice before and
after TBI to correlate performance with the stage of injury.
Minocycline is effective when administered between 45 min -4 hours following a
traumatic brain injury [16]. The research expands on this knowledge by correlating acute
drug administration to axonal damage and resolution. Furthermore, since it is not always
plausible to treat individuals immediately following an injury, this research expanded the
therapeutic window out to 72 hours and determined if its effect is comparable to acute
administration at both a cellular and behavioral level.
Finally, non-viral vectors, specifically a polyplex micellar carrier with therapeutic
compounds, has shown promise in reducing astrogliosis and facilitating axonal
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regeneration when used in a rat model of spinal cord injury. The research described in
Chapter 6 expands these studies; it uses an in vivo, murine model to demonstrate the
ability of these micelles to diffuse in the brain. Micelles were locally injected into the
brain and drug diffusion was imaged over the course of 3 days through a cranial window.
Overall, the project demonstrates the effectiveness of a novel longitudinal
imaging system for use in preclinical trials. The device can collect high cellular
resolution images in deep regions of the brain, an area inaccessible by current imaging
modalities. The device was successfully used in two different murine brain injury models,
collected images for longitudinal brain dynamic measurements, and demonstrated the
benefits of two therapeutics.
1.2.1

Hypothesis
By using GRIN lens technology, the efficacy of candidate therapies for brain

injuries can be measured. Annexin A1, an endogenous protein, can modulate
neuroinflammation by inhibiting microglia activation when administered 6 and 18 hour
post ischemia/reperfusion. Minocycline can prevent axonal degeneration following a
model of TBI when administered beginning at 72 hours post TBI. Furthermore, a
polyplex micelle has shown potential in facilitating axonal regeneration after spinal cord
injury in rats. This same micelle carrier can be used in a murine model and diffuses in the
brain after a local injection.
1.2.2

Specific Aims
In order to test these hypotheses, the following aims were accomplished:
1. Modify a previously developed imaging device such that it is applicable to
brain injury models and potential therapy development.
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2. Measure microglia dynamics 24 hours after ischemia/reperfusion (stroke) and
AnxA1 treatment.
3. Measure progressive axonal degeneration following induced TBI and
minocycline treatment over the course of 30 days.
4. Demonstrate diffusion of PgP-pβgal, a polyplex micelle carrier, after a local
injection in a murine model.

1.3
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CHAPTER 2
BACKGROUND
2.1

Traumatic Brain Injury

Traumatic brain injury has affected and continues to affect a large part of the
population. Traumatic brain injury can lead to disabilities, including cognition, sensory,
and behavioral problems [17], [18]. Most patients, if they recover consciousness, still
suffer from cognitive problems, including many of their higher order thinking skills.
Most commonly, they suffer from short and long term memory loss and become
distracted easily, leading to deficits in planning and organization functionality [19].
Evidence suggests that individuals will suffer from anxiety and depressive behavior for
months and even years after the initial injury [20], [21]. Suffering from a TBI has long
term consequences not just for the individual, but for those around them. Past and ongoing research has examined and defined many of the cognitive and behavioral deficits
following injury. However, the underlying mechanisms of TBI are not yet sufficiently
understood, and additional research at the cellular level is needed to better identify
effective therapeutic targets.
2.1.1

Axons
Information in the brain is transmitted as electrical and chemical signals via the

neurons, which are comprised of a cell soma, dendrites, and an axon. Signals originate at
synapses in dendrites and travel to the soma and down an axon to other neurons. Axonal
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structure is supported by microtubules, which form a unipolar array and facilitate
transport of organelles, proteins, and RNA. Axonal transport is essential for neuronal
function and damage to organization of the microtubules can be detrimental [22].
Myelin, which is produced by oligodendrocytes and considered the white matter
of the brain, is comprised primarily of phospholipids. It functions as the insulator for
axons, where signal propagation occurs. The fluid in the brain contains ions, which aid in
the creation of electrical charge concentrations across the cell membrane and signal
propagation. Along the axon, exist the nodes of Ranvier, which are gaps in the myelin
sheath, exposing the axon to extracellular fluid. Under normal, healthy circumstances, the
conduction of the signal leaps from one node to the next on an axon. When injury occurs,
progressive damage causes a reduction in both myelin and axon quality. As a result the
signal is reduced, and brain function associated with those neurons is impaired [23].
2.1.2

Microglia
Microglia are the resident immune cells of the brain and were identified by Nissl

and Robertson at the end of the 19th century and coined by Pio del Rio Hortega in 1932
[24]. Microglia exhibit a highly ramified morphology with numerous long, tortuous
processes extending in all directions originating at the cell soma. While microglia are
termed resting, their processes are highly mobile, continuously surveying their
environment for disturbances [25].
After injury, microglia respond to extracellular signals and in an effort to maintain
homeostasis will clear cellular debris and toxic substances. When cells die, they release
damage-associated molecular patterns (DAMPs). Microglia are equipped with pattern
recognition receptors and when the DAMPs are detected, microglia produce cytokines
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and chemokines, allowing them to communicate with other cells, further initiating the
inflammatory response. In addition to these receptors, microglia express receptors for
other factors released by injured neurons, including ATP and glutamate. In response to
the released factors, microglia will retract their processes and transform from a ramified
to an amoeboid morphology, resembling macrophages. This change in morphology
allows microglia to proliferate and migrate towards the site of injury [26].
2.1.3

Diffuse Axonal Injury
Traumatic brain injury can be either focal or diffuse, with diffuse axonal injury

(DAI) being the most common. During DAI, acceleration and rotational forces occur and
spatiotemporal pressure variations cause compressive, tensile, and shear strains. The
shape of the skull-brain interface can be described as approximately spherical. Skullbrain movements caused by the accelerative and rotational forces cause a secondary,
spherical pressure wave. The isotropic property of brain tissue causes the spherical wave
front to be conserved as it propagates to the deep regions of the brain. As it travels
deeper, the area of the brain progressively decreases, and as a result the pressure gradient
increases [27]. Consequently, DAI localizes in the white matters of brain, such as the
corpus callosum and the brain stem, areas rich in axons.
As a result of the wave propagation, rapid compressive and tensile forces cause
elongation of axons, damaging the microtubules. A loss of elasticity causes the
microtubules to misalign, and when they reform, areas of swelling, known as varicosities,
develop from interrupted axonal transport. The disorganization of axons and swellings
can lead to disconnection of the axon, resulting in a terminal bulb. Varicosities and
terminal bulbs are both considered hallmarks of brain injury [7].
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In order to visualize white matter damage, diffusion tensor imaging (DTI) has
been widely used. DTI has revealed a decrease in white matter anisotropy with increasing
time following injury, correlating with behavioral problems [28]–[31]. Changes to the
cellular microstructure following damage, cause the diffusion of water to be altered. In a
healthy brain, diffusion is typically not obstructed parallel to the axonal fibers, but
restricted perpendicular to the fibers. If damage occurs, the perpendicular diffusivity
increases while parallel diffusivity decreases, signifying demyelination and axonal
damage [32].
2.1.4

Secondary Injuries
The initial injury causes immediate damage to neurons, axons and blood

vasculature, but it is the secondary injuries that cause many of the deleterious outcomes
of TBI [33]. Secondary axotomy can occur as a result of abnormal calcium homeostasis.
When the axonal membrane is disturbed by the strains of injury, they become leaky,
allowing the influx of calcium. The increased levels of calcium cause enzymes to degrade
key structural proteins and destroy the microtubules. This causes further accumulation of
proteins, leading to additional axonal swellings, and if the axon becomes weak it can
disconnect and form a terminal bulb can occur [34].
When neurons become damaged, they release cytokines and other proinflammatory molecules into the surrounding area. As a result, both resident and
infiltrating immune cells are recruited to the site of damage, leading to chronic
inflammation [35]. As part of the secondary injury cascade, microglia will react to the
injury by becoming activated and remain activated for years after injury has occurred
[36], [37]. Microglia activity was shown to relate to axonal irregularities in both humans
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and rodents; microglia DNA was found in white matter regions months after the injury
had occurred [38].
In rodents and humans, progressive axonal degradation occurs in parallel with
behavioral and cognitive deficits [36], [39]. Additionally, this progressive loss is
associated with microglia activation and infiltration [40], [41]. Few treatments are
available to mitigate the deleterious secondary injuries that progressively cause axonal
damage and microglia activation. In order to better address the lack of current options for
TBI, drug candidates and the time frame in which administration would be most effective
must be further explored.
2.2

Stroke

Stroke is the fifth leading cause of death in the United States, with few treatment
options available [42]. Ischemia occurs when the blood vessel becomes obstructed,
preventing blood from traveling to the brain. Typically, the middle cerebral artery, a
major branch supplying blood to the brain, is occluded. As a result, insufficient oxygen
and nutrients are delivered and cellular homeostasis is disrupted leading to cell death. At
the core of the stroke, the area with the highest blood flow restriction, cell death occurs
within the first few minutes and is nearly wide spread at 24 hours [43]. In the penumbra,
the area less affected by the occlusion, cell death occurs more slowly through apoptosis.
As a result, targeting this area, offers an opportunity for therapeutic intervention [44].
When the brain is deprived of oxygen and blood glucose during the ischemic
phase, cells die, releasing damage signals into the environment, including ATP.
Microglia become activated, phagocytosing debris and secreting proinflammatory
molecules, leading to further tissue damage. However, microglia have also been shown to
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secrete IL-10 and TGF-β, anti-inflammatory cytokines, and mice completely devoid of
microglia have larger infarcts. As a result, microglia may be destructive during the repair
phase, but their presence is needed to aid in alleviating the injury [45].
Only one drug therapy is available for stroke, tissue plasminogen factor (tPA).
This factor is administered intravenously and works by dissolving the clot. It is only
effective within the first few hours of stroke and the longer the treatment is delayed, the
less effective it is. Additionally, tPA only addresses the occlusion in ischemia and not the
secondary injuries [11]. As a result, a therapy that can intervene and modulate
inflammation is needed.
2.3
2.3.1

Longitudinal In Vivo Imaging Methods

Multiphoton Microscopy
Biological tissue naturally scatters light, making it difficult to image deep brain

animal tissue with linear imaging techniques such as bright field and fluorescence
imaging. Multiphoton microscopy (MPM), recognized as the gold standard for in vivo
imaging, is a non-linear optical method that uses near infrared light to excite photons in
vivo from fluorescent structures. The fluorescence may come from labeling techniques
such as transgenic mice or injectable fluorescent dyes. With the development of turnkey
mode-locked laser systems, multiphoton microscopy can be used without extreme
complexity.
Two photon absorption is a rare event. Two photons must arrive within
approximately 0.5 fs of each other at a fluorescent molecule and combine their energies
to cause the molecule to transition to an excited state. However, advances in the
technology have made it possible to increase the probability on this excitation event. The
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setup of MPM requires an ultrafast pulsed laser source and an excitation pathway. Mode
locked lasers generate ultrashort light pulses at a rate of 100 MHz. As a result, the laser is
essentially off more than it is on. Typically, high numerical aperture objectives are used,
compressing photons in space. The combination of compressed laser power in time and
photons in space leads to a higher probability of an excitation event. MPM relies on
multiple photons being absorbed simultaneously, and as a result, it depends on photon
concentration [46], [47].
Two-photon excitation is used to generate fluorescence. Two photons, each with
one-half the energy needed to excite the molecule, must simultaneously be absorbed.
Because wavelength and photon energy are inversely related, and the incident photons
will have a wavelength that is two times the wavelength required in single photon
excitation. This longer incident wavelength leads to an inverse Stokes shift, where the
emitted signal has a shorter wavelength than the excitation source. Appropriate filters are
used to collect the fluorescence of interest and an image can be reconstructed [48].
Multiphoton microscopy offers advantages over the use of one photon, continuous
laser light used in confocal microscopy. MPM uses a longer wavelength, which leads to
less light scattering and allows for deeper penetration of tissue. Confocal microscopy is
limited to visualizing tissue about 100 µm below the surface of the brain, while MPM can
penetrate depths between 500-600 µm[47]. The high density of laser light that can
produce two-photon excitation of fluorophores, which is necessary for visualization, only
occurs at the focal point of the laser beam and not throughout the entire area of tissue,
minimizing background fluorescence. In contrast, confocal illumination bathes the entire
thickness of the sample with higher energy light that can bleach fluorophores and damage
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tissue regardless of the focal plane for imaging. MPM uses a raster scanning beam and
therefore, the high energy focal point is constantly moving. As a result, photo bleaching
of fluorophores and tissue damage are reduced [49], [50]. For these reasons, multiphoton
microscopy remains the preferred choice for in vivo imaging over confocal or wide field
fluorescence imaging.
Chronic in vivo imaging of the brain is necessary to fully understand the
progression of disease and injury. Over the years, several methods have been employed
with multiphoton microscopy to accomplish this goal. Cranial windows and thin skulled
windows are most often used to image the upper cortex of the brain, while gradient
refractive index lenses allow researchers to peer deeper into the brain.
2.3.2

Cranial Windows
Cranial windows were developed by Dr. Karel Svoboda and when properly

executed, allow the observation of the same cortical area over time spans from minutes to
months [51]. A craniectomy, in which a circular portion of the skull is removed, creates a
window for observation. Depending on the application, the dura matter can be removed
or left intact. Typically, low-melt agarose gel is placed between the brain and window to
prevent damage and protect the brain from outside particles[52]. In some applications,
the overlying cortical tissue can be removed to prevent light scattering from thick brain
tissue[53]. While this approach allows us to obtain high resolution images of deep brain
tissue, this method is considered highly invasive as a large area of tissue is removed.
Cranial windows have been effective in a range of applications including the
study of synaptic plasticity, calcium dynamics, and neuroinflammation in disease models.
This imaging technique has been successfully applied to a variety of transgenic mouse
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models and injectable dyes. Dendritic spines, involved in synaptic plasticity, have been
longitudinally imaged to demonstrate their stability and loss in both naïve and disease
models of mice [53]–[56].
Calcium dyes can be injected into the desired imaging area and a cranial window
can be placed to reveal the activity of dense neuronal networks, offering method that is
less invasive than electrophysiological recordings [57]–[59]. To look at calcium
dynamics long-term, cells can be chronically labeled with viral vectors, again offering an
advantageous approach over chronically implanted electrodes, such that it eliminates
degradation caused by cell death and gliosis at the electrode tips [60]. Cranial windows
have been further developed to be stable over time allowing the imaging of neuronal
activity in awake mice in order to map behavior-related neuronal dynamics [61], [62].
In models of stroke, cranial windows have been used to examine brain dynamics
following injury. Longitudinal in vivo imaging of apical dendritic arbors demonstrated
before the induction of stroke, dendritic arbors are relatively stable and following injury,
significant remodeling occurred as shown by dendritic tip growth and retraction [63].
Microglia dynamics have been longitudinally studied in vivo with the use of cranial
windows, demonstrating their role and tendency to become activated, proliferate, and
interact with the blood vasculature after models of stroke [64]–[66] .
2.3.3

Thinned Skull Windows
The use of thinned skull windows with multiphoton microscopy is a popular

technique, which limits the amount of biological tissue the laser travels through while
simultaneously protecting the brain from external factors, such as temperature and
pressure [67]. When the skull is removed, as in the case of cranial windows, glia cells
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become activated and can lead to changes the brain dynamics, inherently effecting the
scientific study. Thinned skull windows have the advantage of decreased inflammation
[68]. In the neocortex, thinned skull windows have allowed researchers to visualize
dendritic spines as well as perform longitudinal imaging in which the changes in
dendritic segments are imaged in layers 5 of the brain [54], [69].
A disadvantage with thinned skull windows is the need to re-perform skull
thinning as the bone regrows over time. To circumvent this disadvantage, researchers
have developed methods, such as reinforcing the thin skull with transparent cement and
glass windows, allowing visibility up to 250 µm below the pial surface over a 3 month
time period [70]. An additional disadvantage to this technique is the skull is considered a
highly chaotic tissue and light will be severely distorted before reaching the point of
focus. Wave fronts can be controlled with adaptive optics and fluorescence signal can be
increased and subsequently increase the field of view area [71]. The depth of the field of
view is limited and inherently based on the thickness of the skull after thinning. In order
to obtain high resolution images, the skull thickness should be between 15-25 µm, as this
can potentially lead to damaged brain tissue [72].
Thinned skull windows have been used to study a variety disease models,
including ALS, Alzheimer’s, and stroke. In ALS, the thinned skull technique was used to
visualize excitotoxicity by identifying dendritic blebbing [73]. In Alzheimer’s, this
method is used to successfully image senile plaques in living animals in the same brain
region over a period of days to months [74], [75]. Brain dynamics have been studied
following various models of stroke. Calcium transients are associated with sensory
processing and rewiring months after an ischemic stroke [76]. A longitudinally used
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thinned skull window revealed increased microglia reactivity and the entrance of
circulating cells into the parenchyma because the blood brain barrier became
compromised [77].
While both cranial and thin skulled windows have provided insights in various
disease models, the majority of data collected has been limited to the upper regions of the
brain. While some in vivo information has been collected in lower levels of the cortex
[53], it typically involves the removal of brain tissue, which can interfere with data
collection and analysis. As a result, optical devices are needed that can extend the
imaging depth and provide longitudinal data while causing minimal brain impairment.
2.3.4

Gradient Refractive Index Lenses
Light scattering from brain tissue is a challenge presented when attempting to

image neural activity in the brain. Deep regions of brain have remained inaccessible, as
they are beyond the working distance of current modalities. To circumvent this challenge,
gradient refractive index (GRIN) lenses can be used in vivo to explore deeper regions of
brain. GRIN lenses can provide the high cellular resolution needed to better understand
brain activity and to study the progression of brain trauma.
GRIN lenses, a class of micro lenses, are glass cylinder, biocompatible lenses
used to examine deep brain structures [14], [15], [78]. The lenses use a negative gradient
in the refractive index of glass from the center of the lens to the outside edge to bend and
focus light. The lenses have flat surfaces which allows for ease in manufacturing a
system to implant [79]. The glass is inhomogenously doped with cation species, with the
highest density of cations at the central axis of the lens and declining radially towards the
outer edge. Total internal reflection occurs gradually as light passes from the central
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regions to the periphery. As a result, the light will travel through the lens in a sinusoidal
path [80].
GRIN lenses are characterized by their pitch, length, or numerical aperture. The
pitch represents the number of internal images made inside the lens, determined by the
refractive index profile. GRIN lenses can be up to tens of centimeters long, which is more
than capable of imaging in animals and even humans. When GRIN lenses are combined
with multiphoton microscopy, they can resolve optical planes far from the surface of the
lens which is beneficial because implantation of the lens may cause mechanical damage
or may initiate an immune response next to the lens [14].
GRIN lenses alone generally have a numerical aperture, which is related to the
resolving power, of 0.5. While these lenses have enabled microendoscopes to be used in
small animal research applications, the optical resolution is not comparable to
conventional microscopy. Single GRIN lenses have several optical drawbacks, such as a
highly elongated point spread function, which hinders the ability to collect high
resolution three dimensional image stacks [78], [79]. GRIN lenses can be optimized by
combing additional refractive index matched elements leading to high numerical
apertures and allowing for the collection of high resolution data that are needed in studies
such as neuronal plasticity and resident immune cell response[78], [81].
GRIN lenses have been used in a variety of applications to demonstrate their
functionality in vivo and to collect data concerning neural networks. GRIN lenses have
been used to visualize the activity of deeply buried neurons in the substantia nigra, lateral
hypothalamus, and hippocampus [48], [51], [52]. Lower levels of the prefrontal cortex
can be imaged with minimal glia scarring and without interrupting the animal’s behavior
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[14]. Longitudinal images of deep brain structures with GRIN lenses have revealed the
extreme stability of dendrites and rare instances of their alterations[83]. In order to image
calcium transients in awake and behaving mice, GRIN lenses have been used in
endoscopes and ultrafast camera systems [84], [85], establishing their potential to be used
to study not only resting brain dynamics.
GRIN lens technology has been useful in collecting longitudinal data with high
cellular resolution. This technology can be further used to study the progression of high
incidence brain injuries, such as stroke and traumatic brain injury. A GRIN lens can be
implanted long-term into transgenic mice without interrupting animal behavior [14],
offering an opportunity to study both brain structural changes and behavior following
injury in the same mouse. Additionally, GRIN lens technology would be useful as a
preclinical tool. It is important to understand when and how candidate therapies are
affecting the outcome, and if this outcome is long term. Since GRIN lenses can collect
both spatial and temporal data from the same mouse, they offer a unique opportunity to
accomplish this goal.
2.4
2.4.1

Candidate Therapies for Brain Injury

Minocycline
Finding an effective treatment for traumatic brain injury remains a challenge in

the scientific community. Despite the ongoing research and the substantial investments in
this field, traumatic brain injury still remains a major source of disability in the world.
Both the mechanical and cellular damage disrupt cognition and everyday life for
individuals suffering from a traumatic brain injury, and as a result it is imperative to find
a treatment which can limit and reverse the deleterious effects of the injury. An FDA
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approved drug, minocycline, has shown preclinical potential as a therapeutic when
administered acutely (< 24 hr) following a traumatic brain injury.
Minocycline belongs to the tetracycline family of antimicrobials, is considered a
broad spectrum antibiotic, and has been in use for over 30 years. Minocycline can be
administered both intravenously and orally, and it has a long half-life [86]. Because it is
also a highly lipophilic molecule, it can easily pass through the blood brain barrier
leading to an accumulation in the cells of the central nervous system [87]. It can be used
chronically in high doses and is well tolerated in humans [88].
The antibiotic effects of tetracyclines has been known since the early 1940s, and
recently, their non-antibiotic properties have been studied, including their antiinflammatory, antiapoptotic, and antioxidant benefits. Minocycline has been shown to be
beneficial for many inflammatory diseases and has emerged as effective in
neuroprotection and confirmed in experimental models of ischemia and traumatic brain
injury [86].
At high dosages, minocycline inhibits inflammatory cells, including microglia, T
cells, and neutrophils. It has also been shown to block both caspase-dependent and
independent apoptosis, inhibit metaloproteases, and scavenge for reactive oxygen species.
As a result of these properties, the drug has been studied at administration between 45
minutes and 4 hours in several pre-clinical models of TBI [89].
Early administration of minocycline has shown to suppress markers of
neuroinflammation, namely activated microglia and macrophage densities, which can
account for neuronal loss. Early inflammatory outcomes were examined following TBI
and it was found that at both one and four days after a closed head injury model, the
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number of activated microglia in minocycline-treated animals was significantly less than
in the saline treated group, demonstrating the early protective effects of minocycline [90].
In a closed head injury model using the weight drop method, minocycline was
administered at 5 minutes post injury and long term histopathological outcomes were
studied. Three months after injury, minocycline was shown to protect the volume
(ipsilateral/contralateral) of the corpus callosum, striatum, and lateral ventricle when
compared to naïve mice. Additionally, the treatment reduced the number of both GFAP+
and CD11b+ cells, which are markers for astrocytes and microglia, respectively. The
results demonstrate than when minocycline is administered acutely following closed head
injury, it exhibits a long term, protective effect [91].
Another study used the same model and minocycline treatment set up to examine
both the drug’s acute and chronic effect on preclinical neurological outcomes. One of the
best markers for diffuse axonal injury is the accumulation of β-amyloid precursor protein
(β-APP). This protein accumulates within hours following traumatic brain injury because
disrupted axonal protein transport causes it to pool at the site of impaired tissue.
Following TBI, the number of β-APP labeled axons increased markedly, independent of
treatment, signifying that the mechanical damage occurring during diffuse axonal injury
cannot be protected by the drug. However, minocycline did decrease the number of
CD11b+ cells, demonstrating its effect on neuroinflammation [92].
Memory impairment, anxiety, and depression manifest following traumatic brain
injury, a result of the mechanical and cellular damage. Minocycline, when administered
acutely improves recognition memory when evaluated long term [93]. Additionally,
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minocycline improves both acute and long term functional behavior after a closed head
injury in mice, as compared to vehicle treated mice [92], [94].
Minocycline is neuroprotective when administered between one and four hours,
but it is not always possible to treat individuals in such a short time window. Therefore, it
is necessary to determine if the drug is still effective when administered in a longer
therapeutic window. Additionally, the studies conducted have looked at fixed brain slices,
which are a snapshot it time. It is not only necessary to identify the efficacy of
minocycline treatment, but also how it affects the progression of axonal damage.
2.4.2

Annexin A1
Annexin A1 (AnxA1) was first discovered in the 1970s and is a 37-kDA member

of the annexin superfamily. This molecule is expressed in subcellular granules of
monocytes and neutrophils [95]. AnxA1 modulates various biological events, including
both acute and chronic inflammation [96]. AnxA1 causes L-selectin on neutrophils to
shed and leukocytes to detach from the endothelium, contributing to the protein’s ability
to restrict transmigration from the vasculature to tissue that is seen in inflammation. Anx1
must be internalized to exhibit its anti-inflammatory effects. When cells become
activated, AnxA1 is released. Following release, AnxA1 becomes cleaved causing it to
either act as a pro-drug or produce homeostasis by limiting the action of AnxA1 [97].
As a result of reperfusion injury, chemokines and cellular adhesion molecules
(CAM) are expressed, which causes leukocytes to migrate into the damaged tissue.
Additionally, resident microglia become activated, leading to excessive inflammation.
When this occurs, endogenous strategies involving the glucocorticoid regulated protein,
AnxA1, are initiated by the immune cells. AnxA1 modulates the inflammatory response
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by targeting the formyl peptide receptor 2 (FPR2) as demonstrated by the administration
of a known antagonist, Boc2. When Boc2 is administered simultaneously with AnxA1,
the anti-inflammatory properties of AnxA1 are negated [98]. To further establish the antiinflammatory effect of AnxA1, an AnxA1-/- mouse was developed and has demonstrated
that when AnxA1 is absent, inflammation is exacerbated [99]. When exogenous AnxA1
was administered to animals undergoing ischemia/reperfusion injury, leukocyte adhesion
and rolling was significantly decreased, reducing the inflammatory response normally
seen in this disease model [96], [100].
AnxA1 is endogenously expressed in microglia and it has been demonstrated, in
vitro, that exogenous AnxA1 promotes the phagocytosis of apoptotic neurons and
promotes the resolution of inflammatory microglial activation. This demonstrates AnxA1
has a fundamental role in brain homeostasis and the administration of exogenous AnxA1
may be potentially effective as a therapeutic for neuroinflammation [101]. Further
research is needed to determine if AnxA1 exhibits this same protection in vivo following
ischemia/reperfusion.
2.4.3

PgP-pβ-Gal
Therapeutic nucleic acids capable of changing gene expression levels may be

advantageous in the treatment of axonal regeneration. In gene therapy, vectors containing
genetic material capable of expressing a therapeutic gene are delivered intracellularly.
Viral vectors are commonly used to deliver and achieve transfection, but they lack
specificity, can cause an immune response, and lead to inflammation. In injuries such as
stroke and TBI, inflammation has a key role in further mitigating damage. Introducing
therapeutic compounds that further cause inflammation would be inefficient, and
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therefore, it is necessary to use a transfection system that eliminates these concerns and
can achieve delivery in the central nervous system. Non-viral vectors are being
developed, such as plasmid DNA and siRNA. These vectors are formulated with cationic
lipids or polymer carriers, which are not only easy to manufacture at a large scale, but
reduce off target effects and diminish an inflammatory response [102].
A synthetic polymer that has shown promise by its ability to transfect DNA
vectors in the CNS is polyethylenimine (PEI). However, in the presence of serum, the
transfection efficiency of PEI is low and cytotoxic. To overcome these limitations,
polymeric micelles for combinatorial drug/gene delivery are being developed. The
cationic amphiphilic copolymer, poly(lactide-co-glycolide)-graft-polyethylenimine (PgP)
has been synthetized as an efficient vector for stable intracellular delivery of nucleic
acids. PgP micelles loaded with reporter genes and siRNA (PgP polyplexes) can transfect
cells in the rat spinal cord in vivo as well as reduce cytotoxicity as compared to
conventional PEI. As a result, PgP may be an effective choice for gene delivery [103].
Since PgP has shown to deliver DNA to the normal rat spinal cord, the ability of
PgP to deliver siRhoA in a rat compression spinal cord injury model was investigated.
The results demonstrated that after local injection of the micelles loaded with siRhoA,
apoptosis and astrogliosis were reduced. Furthermore, axonal regeneration was increased
as compared to the untreated SCI animal groups [104]. These results are encouraging,
and PgP complexed with siRhoA and other therapeutic biomolecules may be a candidate
for treating diffuse axonal injury (DAI). DAI is a progressive injury and can result in
widespread axon degeneration and microglia activation. Based on the PgP’s ability to
carry drugs that reduce inflammation and increasing axonal regeneration, it may be an
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effective therapeutic in not only delivery of anti-inflammatory drugs but also reversing
the progressive damage.

CHAPTER 3
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CHAPTER 4
TRIO PLATFORM: A NOVEL LOW PROFILE
IN VIVO IMAGING SUPPORT AND
RESTRAINT SYSTEM FOR MICE

4.1

Introduction

Laser scanning confocal microscopy through cortical windows has opened upper
layers of the mouse brain for high resolution, time-course, in vivo imaging [105], [106],
and multiphoton microscopy (MPM) has facilitated in vivo imaging of the olfactory bulb
[107] and lower layers of the cortex, up to several hundred microns deep [79].
Additionally, implanted GRIN lenses have extended the reach of MPM to lower cortical
and subcortical regions of the murine brain [78], [79], [83] and small prisms have
provided vertical views of entire cortical columns [108]. These technological
achievements have met at a crossroad with the rapid growth in the number of transgenic
mouse strains to achieve unprecedented spatiotemporal resolution of dynamic processes
in the brain. Transgenic mice with fluorescent proteins expressed under specific genetic
promoters have permitted cell-type specific identification of targeted cell populations.
Investigators have used in vivo imaging on these mice to observed processes such as
changes in dendritic spine density [109], migration and activation of microglia [110],
growth of brain tumors [83], [106], and the dynamics of a brain tumor microenvironment
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[111]. Additionally, genetically encoded calcium sensitive fluorescent proteins [112],
[113] and dyes [51], [112] have revealed the activity of local and large scale neuronal
networks [114]. Furthermore, by counterstaining the vasculature, blood flow rates have
been determined [79], [115], and vessel permeability and leukocyte trafficking have been
observed [116]. The ability to monitor these activities over time in a mouse model has
tremendous importance to both basic research and preclinical studies [111], [117]. Yet,
the means by which mice are positioned and maintained for imaging has relied primarily
on old technology and non-standardized custom made components.
Positioning and maintaining anesthetized mice for imaging over time requires a
means to secure the head, maintain the animal’s body temperature and facilitate delivery
of anesthesia. Securely restraining the animal’s head during imaging is essential for
reducing motion artifacts from respiration and heart beats [116]. A good restraint system
will also optimize the alignment of the imaging region with microscope objective [78],
[116]. Repeatable alignment is important for longitudinal experiments and is critically
important for imaging through implanted GRIN lenses [118].
Numerous methods of restraining mice via head fixation for in vivo imaging have
been reported. These mainly include stereotaxic devices [111] many of which are custom
fabricated for a particular research lab [106], [107], [116], and involve custom designed
stages [113], and custom-made bars or plates (head posts) permanently affixed to the
head with customized stage-mounted devices that secure the head post [61], [109], [113],
[119]. Several commercially available head immobilization devices are available that can
restrain the head for imaging through cranial windows. Examples include the MAG-1
Simple Head Holder Plate for Mice from Narishige International USA, Inc. and mouse
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and neonatal rat adaptors from Stoelting Co. and Harvard Apparatus, Harvard
Biosciences, Inc. However, these devices are 4 – 7.5 centimeters tall, which is greater
than the distance between the stage and the objective lens on some microscope systems.
Three-point immobilization devices with ear bars and a bite bar are smaller than
stereotaxic frames and will securely immobilize the head, but these have rudimentary
adjustments for pitch, yaw, and roll. This limited adjustability makes it difficult to
consistently align the head over multiple imaging sessions for longitudinal studies. Some
custom head plate and holder systems have a much smaller size and consistent alignment
for imaging through cranial windows. Unfortunately, recreating custom components can
pose a challenge when attempting to use another lab’s protocol. Notably, no low profile,
commercially available systems were identified that can achieve the repeatable, sensitive
alignment needed for repeated imaging through an implanted GRIN lens.
Gas anesthesia may be used for long in vivo imaging sessions to avoid unwanted
movement caused by injection of anesthetic agents and to avoid light contamination when
opening a shroud to make an injection. However, the nose cones for gas anesthesia are
usually configured to mount onto stereotaxic frames and few studies use stereotaxic
frames for in vivo imaging [106], [111], presumably, because of their large size.
Alternatively, a simple plastic cone can be attached to the hose from the vaporizer. The
open end of the cone is covered with the top half of a rubber balloon with a slit in it. The
nose of the mouse is placed in the slit of the cone, but if the slit is not properly sized,
anesthetic gas can leak into the room (personal observation) unless a scavenger system is
installed. This system increases the amount of space occupied by components on and
around the microscope stage and can substantially increase setup time.
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Prolonged anesthesia will cause a drop in body temperature to hypothermic levels
if left unchecked [120]. Two commonly used types of systems are electrical,
thermostatically controlled resistive heating plates or pads and warm water pads.
Electrical plates are thin and fit well under microscope objectives. Both the electrical
plates and pads pose a risk of overheating the animal if the temperature probe is
improperly placed or it becomes dislodged. Warm water pads use circulating water that is
warmed in a reservoir to a set temperature, such as 37˚ C. Its thermostat is located inside
the water tank, which greatly reduces the possibility of overheating the animal.
Unfortunately, these pads are bulky and raise the height of the mouse by several
millimeters or more. They can also be uneven and thus, require the operator to expend
additional time to move the pad to achieve proper head alignment. To our knowledge,
none of these heating systems provide head fixation. A heating pad with a standard
immobilization frame raises the height of the mouse’s head to over 7 cm.
4.2
4.2.1

Materials and Methods

TRIO Design and Construction
The system was designed to restrain the head of an anesthetized mouse with a

head plate (or head post) attached to the skull and to orient the cranial window so that the
flat face of the window is perpendicular to a microscope objective (Figure 31). The
system was also designed to provide gas anesthesia and to maintain body temperature.
The components of the system were designed in SolidWorks (Dassault Systèmes). A
MakerBot® Replicator® 2 three-dimensional (3D) printer and poly(lactic acid) (PLA)
filament were used to fabricate the system. This manufacturing method minimized
development time and costs, allowing for multiple design iterations. The widespread
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availability of 3D printers enables other researchers to replicate or modify the design as
their experiments require.

Figure 31. TRIO Platform: an in vivo integrated imaging support system. (A) TRIO
Platform with gas anesthesia supplied by a compact, portable gas anesthesia system
(SomnoSuite®, Kent Scientific Corp.). Isoflurane is supplied from a syringe (white
arrow). The integrated digital vaporizer (yellow arrow) is much smaller than traditional
vaporizers which markedly reduces the amount of anesthesia used for surgeries and for
imaging sessions. (B) Anesthetized mouse positioned and warmed for imaging using the
TRIO Platform on the stage of a multiphoton microscope. The overall height of the base
plate with circulating warm water and the mouse head is only 20 mm. This relatively
small height will enable its use on a wider range of microscopes. (The white paper towels
around the platform were used to block reflections from the lights used for this photo.
They are not required for imaging.) The compact anesthesia system can be placed to the
side of the stage within the microscope enclosure or outside of the enclosure [15].
4.2.2

Warm Water Plate
A 3D printed plate with an interior, serpentine channel for warm water circulation

serves as the central hub of the system (Figure 32). The plate was designed with a lowprofile rectangular geometry that is 5 mm high, 115 mm long and 61 mm wide. Water
inlet and outlet ports were placed at opposing corners and fitted with standard tube
fittings to allow attachment of polymer tubing to deliver warm water and recycle it back
to the warm water reservoir. Water in the reservoir was maintained at 40˚ C. A flat cover
was attached to the top of the water chamber with cyanoacrylate adhesive (Loctite). The
entire chamber was sealed with a silicone adhesive (Kwik Sil, World Precision
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Instruments, Sarasota, FL, USA) to prevent leaks. This system has been used for 9
months without any water leaks.

Figure 32. Integrated system with the top cover of the base plate removed to show the
serpentine water channel. Parts were 3D printed and designed in SolidWorks®.
Dimensions are in mm [15].
4.2.3

Anesthesia Nose Cone
To deliver a gaseous anesthetic, a slotted tongue (Figure 3-3A, arrow) was glued

to the front of the printed plate and a 3D printed nose cone (Figure 3-3B-C). The channel
under the nose cone (Figure 3-3B, arrow) slides into the tongue's slot and is held in
place by a triangular catch, preventing it from being dislodged accidently. The cone can
be removed for cleaning or when a non-gaseous anesthetic is being used.

Figure 33. Components of TRIO Platform. A. This view shows features of the base plate
that cannot be seen in Figure 32, such as the extensions of the base plate for attaching the
head plate holder posts (arrowheads) and the slotted tongue (arrow) for attaching the
nose cone. (B-C) Two views of nose cone design. Channel under nose cone in (B, arrow)
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sides into a slot in the tongue (A, arrow). D. Gas inlet (right side) and outlet (left side)
are integrated into one piece that attaches to the tubular component of the nose cone (C,
arrow). Dimensions are in mm [15].
A t-shaped gas delivery fitting also printed with PLA (Figure 3-3D) is connected
to an opening in the cone (Figure 3-3C, arrow). One side has a tube fitting that connects
to the inlet hose from a compact gas anesthesia system. The other side connects to the
hose that returns gas to the anesthesia system where the scavenged gas is trapped in an
activated charcoal filter. Both hoses are made of silicone tubing (FDA-grade, Platinumcured silicone tubing, 1/8” ID x 3/16” OD, VWR International). We used a SomnoSuiteTM
anesthesia system (Kent Scientific Corp.) because it fits easily within or near the housing
that surrounds our multiphoton microscope, which was a VivoTM 2-Photon Microscopy
Workstation (Intelligent Imaging Innovations, Inc., also written as 3i, Inc.). To make
isoflurane delivery more efficient and minimize leaks of anesthetic into the workspace,
an elastomer shroud (AC-COAX-Balloon, Kent Scientific Corp.) is secured over the
opening of the nose cone with a piece of ½-wide plastic tape (Figure 3-4, arrow). The
elastomer covering can be lifted temporarily to confirm that the animal’s nose is place
fully in the cone. A medium-sized rubber balloon with the neck piece removed will work
equally as well. We have also used a piece of 18-gauge wire, instead of tape, to secure the
shroud to the gas delivery tube. The shroud was easily replaced when the edges of the
rubber dried and cracked after several months of use.
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Figure 34. TRIO Platform 3D-printed system. (A) Assembled system with tube fittings
for attachment to inlet (Iw) and outlet (Ow) water lines and Luer lock fittings for
attachment of inlet (Ig) and outlet (Og) tubes from a gas anesthesia system. The
elastomeric shroud is held onto the nose cone with plastic tape from the underside of the
device (black arrow). (B) Head plate holder posts and machine screws. Two screws are
placed in holes in the base plate and screwed into tapped holes in the posts (black
arrows) to attach the posts to the base plate. A square hole in the post holds an arm of the
head plate holder (black arrowhead) and a round taped hole in the post (white
arrowhead) holds a set screw (C) to secure the position of the arm in the square hole.
(C) Head plate holders with the accompanying screws that secure the head plate holders
to the holder posts [15].
In order to add a head plate holder securely to the base plate, the two front corners
of the base plate have two 21 mm square extensions that are printed as part of the bottom
plate (Figure 3-3A, arrowheads). The posts are attached to these extensions with 3-mm
hex head machine screws 8 mm in length. The posts are rectangular columns, 22 mm in
height. Each post has two 8-mm long holes in the bottom (Figure 3-4B, black arrows)
that are tapped to match the thread pitch of the 3-mm hex head machine screws that hold
the post to the base plate. Each post also has a square hole (4 mm x 4 mm, black
arrowhead) that holds the long arm of a head plate holder (Figure 3-4C), and one 3-mm
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circular hole (white arrowhead) that is tapped to match the thread pitch of a 3-mm set
screw with a knurled head for hand tightening. The long arm of each of the two head
plate holders has a square profile that fits snugly into the square holes in the holder posts.
The arm can be securely positioned in the post by tightening the set screw by hand until
the arm does not move with gentle pressure. The screw must not be overtightened as
overtightening will cut into the plastic and shorten the life of the holder. The t-shaped
end of each bar has a 1-mm high by 1-mm deep by 12 mm long rectangular cavity
(Figure 3-3, inset), which holds the outer end of a head plate. Together, both bars
securely hold the head plate and orient it such that the cranial window is perpendicular to
the laser beam.
4.2.4

Head Plate Assembly
SolidWorks and 3D printing with a PLA filament (G-Star Technologies) were

used to design and fabricate head plates, respectively. We used a polymer head plate
instead of a metal plate or bar to minimize the mass of the plate and permit easy
modification of the number of ports and their placement. Minimizing the mass of the
head plate, which was about 0.2 g, was important for our work because many of our mice
are used for behavioral experiments in between imaging sessions [117].
The head plates are 9 mm long, which is long enough to have free ends to attach
to the head plate holders (Figures 3-2 and 3-5) and short enough to provide free
movement when the mouse is awake (Figure 3-6). A section at the caudal edge is cut
out, providing an opening for installation of an injury hub which was used for midline
fluid percussion experiments to induce traumatic brain injury [121]. If the hub is not
needed, the cutout provides additional surface area for applying adhesive. A second
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cutout (Figure 3-5), provides a place to attach a 5 mm diameter glass cover slip cranial
window.

Figure 35. Two head plate holders grip each side of a head plate. The head plate is
permanently attached to the skull of a mouse. Head plate holder posts position the holders
and head plate above the base plate with sufficient space for positioning the head of an
adult mouse (see Figure 3-1B). The entire assembly is 22 mm tall, 14 mm wide, and just
under 100 mm long. Inset. Detailed view of a head plate holder. The long arm has a
square cross section (3.7 mm x 3.7 mm) that fits into a square hole in a holder post. One
end of the head plate fits into the slot in the t-shaped end. The slot is 12 mm long, 1 mm
wide and 1 mm deep. The overall width is 14 mm and the overall length is 41 mm. These
dimensions can be adjusted for different sized head plates [15].

Figure 36. Mouse with an implanted GRIN lens and permanently attached head plate.
Prior to surgery, a GRIN lens was affixed to a 5 mm diameter cover slip which was then
glued to the head plate. The lens was implanted into the brain by lowering it through a
craniotomy and advancing it into the brain as the head plate was slowly lowered to the
skull (see Figure 3-7) [15].
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Optical adhesive (Number 71 Adhesive, Norland Products, Cranbury, NJ, USA) is
used to secure the cover slip to the head plate. A thin bead of adhesive (~1-mm wide) is
applied around the edge of the cover slip and then gently pressed against the bottom of
the head plate using blunt, curved forceps so that the adhesive forms a continuous seal.
The head is placed upside down for this step. The optical adhesive is cured using a UV
lamp according to the manufacturer’s instructions. Because UV light is harmful, the
operator must shield eyes and skin from UV light at all times. It is important to confirm
that the coverslip is parallel to the bottom of the head plate which will ensure optimal
alignment of the cranial window for imaging. If the resolution of the printer is not precise
enough, the cover slip may not seat parallel to the head plate. In this case, a 5-mm end
mill and standard machining techniques can be used to mill the area for attachment.
For deep brain imaging in lower cortical layers 4-6 and subcortical regions, a
GRIN lens should be attached to the cranial window, a 5-mm diameter glass cover slip.
The attachment of the GRIN lens to a cover slip has been described in our previous work
[78]. Because the cover slip is mounted on the underside of the head plate, the head plate
should be placed upside down and the coverslip-GRIN lens assembly should be
positioned over an appropriate opening in the head plate with the free end of the GRIN
lens pointed up. The operator should use a stereomicroscope or large magnifying glass
with ample lighting to clearly visualize the forceps and lens and to ensure that the forceps
do not touch the GRIN lens. The forceps can transfer glue and debris onto the lens which
could degrade image quality. It is also possible to chip the edge of the lens or to break it
off the cover slip with sufficient pressure. In our experience, workers become proficient
at making these assemblies in about 2-3 procedures.
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A clean, dust-free or low-dust work area is necessary when the cover slip is
attached to the head plate. This work area reduces potential sources of infection and
maintains optical clarity of the window and/or GRIN lens. Components can be cleaned
with 70% ethanol prior to assembly and any dust particles can be removed before
applying adhesives. Additionally, the UV light used to cure the adhesive disinfects the
exposed surfaces. Assemblies should be transferred after curing using clean forceps and
stored in clean, covered containers. Prior to implantation, assembled head plates should
be exposed to UV light for 15 minutes on each side or soaked in 70% ethanol for 15
minutes to disinfect the surfaces. They should be transferred to the surgical site in sterile
containers. Autoclaving is not recommended as it might warp the polymer head plate.
Ethylene oxide gas was not tested as a means of sterilization.
Because the head plate design is easily modified in SolidWorks® and plates are
quickly printed with an inexpensive polymer, making changes for different types of
imaging experiments is quick and economical.
4.2.5

Printing the Platform
All polymer parts were designed in SolidWorks® and produced on a Replicator

2® (MakerBot®) 3D printer. All pieces were printed at 100% fill with a 0.1 mm layer
height. (Note: Some 3D printers cannot print as small as 0.1 mm/layer.) Optimal 3D
printing of the components of this system requires correct printing orientation. Printing in
another orientation could result in the printer program adding a meshwork of polymer
“supports” to overhanging areas. Without supports, overhanging areas would deform
under the force of gravity. These supports could occlude channels and slots that should be
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left open. Parts with open areas can be oriented such that supports are not needed. We
optimized the orientations for printing each part, as follows:
1. The base of the platform was printed right side up, with the bottom of the device
flat against the platform, with no supports.
2. The top of the device was printed on its widest side (i.e., flat) with no supports.
3. The slotted tongue was printed on its thinnest side so that the slot was
perpendicular to the printer platform. No supports were used.
4. The nose cone was printed with the cylindrical part against the platform, with
supports
5. The gas delivery fitting was printed in two halves, with the inside edges flat
against the platform, with no supports.
6. The head plate holder post was printed laying on its longest side, so that the slot
was perpendicular to the platform, and with no supports.
7. The head plate holder was positioned so that the long arm was pointed straight
into the air and printed with no supports.
4.2.6

Animals for In Vivo Imaging
White, GFAP-GFP+ lab mice (FVB/N-Tg(GFAPGFP)14Mes/J) were obtained

from Jackson Labs. Louisiana Tech University IACUC guidelines were followed for
animal housing with lighting in a 12 h on – 12 h off cycle. Food and water were provided
ad libitum.
4.2.7

Surgery
All surgical and imaging procedures were approved by the Louisiana Tech

University Institutional Animal Care and Use Committee. Every effort was made to
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minimize pain and suffering. A noxious stimulus consisting of two toe pinches every 15
min was used to confirm that animals were in a surgical plane of anesthesia during
surgical procedures. Mice were monitored for recovery until sternal recumbency was
overserved. To minimize post-surgical pain, Ibuprophen, children’s suspension (30
mg/kg/day) was dissolved in the animal’s drinking water for 60 - 72 hours following
surgery. Mice were also monitored daily for signs of distress or poor health. The end
point for mice was perfusion (see histology section).
Prior to performing any procedures, mice were allowed to acclimate to the room
in their home cage for at least 30 minutes. For surgery, a mouse was initially anesthetized
with 3% isoflurane (VEDCO) in the induction chamber of a SomnoSuite® small animal
anesthesia system (Kent Scientific Corp.). A mixture of ketamine (10 mg/kg) and
xylazine (1 mg/kg) in sterile saline was injected intraperitoneally after induction of
anesthesia using the isoflurane chamber. This mixture was used to give surgical staff time
to prep the animal and position it in the stereotaxic frame. Once secured in the frame, the
mice were maintained on 1.5% isoflurane. Ophthalmic ointment was placed on the eyes
and the fur over the scalp was cut with iris scissors. The mouse was then placed in a
Benchmark stereotaxic frame with a nose cone for gas anesthesia (Leica Biosystems) and
a mouse and neonatal rat adaptor (Stoelting Co.). Anesthesia was maintained using 1.5%
isoflurane supplied by the SomnoSuite® system. Body temperature was regulated and
heart rate and SpO2 were monitored using a PhysioSuite® System (Kent Scientific
Corp.).
Aseptic surgery was performed to install either a cranial window or a GRIN lens
mounted on a cranial window, as previously described [78], [117]. Briefly, after
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confirming the mouse was in a surgical plane of anesthesia using noxious toe pinches, an
incision was made in the scalp and connective tissue was cleared.
Under a surgical microscope, a micro drill was used to make a 1 mm diameter
craniectomy at selected rostral and lateral distances with respect to bregma and the
midline, respectively. The exposed dura was removed and a GRIN lens (mounted on a
head plate, as described in the head plate assembly section) was implanted through the
craniectomy.
Before the head plate was attached, a thin layer of cyanoacrylate adhesive (Krazy
Glue®) was applied to the skull [72], [122]. To position the head plate for implanting it
was held by a set of two 3D-printed head plate grips (Figure 37C) mounted to the end of
a steel probe holder (Figure 37B; Stoelting Co.) that was attached to a stereotaxic frame
(Figure 37A). The rostral-caudal and medial-lateral direction controls of the stereotaxic
frame were used to guide the lens to the desired stereotaxic coordinates. The probe holder
control was then lowered until the GRIN lens was touching the pial surface of the brain.
After this, the assembly was lowered at a rate of 0.1 mm/min to the desired depth into the
brain. Once the final depth was reached, cyanoacrylate glue was applied around the head
plate and in any holes in the head plate that were not used for the window, GRIN lens, or
other devices. For some animals, we left the large central hole open for later installation
of an injury hub for inducing a traumatic brain injury using midline fluid percussion
[121]. Stereotaxic coordinates will vary depending on the location of the brain region for
imaging. Insertion depth is limited by the length of the GRIN lens and the angle of
insertion.
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Figure 37. Probe holder with custom grips for surgically attaching head plate. The head
plate is held by a 3D printed head plate grips that are attached to the end of a standard
probe holder for a stereotaxic device. (A) Probe holder with custom grips attached. (B)
View showing details of grips. (C) Grips in use during surgery to attach a head plate. The
cut-out in the head plate around the craniotomy provides room to attach an injury hub for
a fluid percussion injury, however, a glass cover slip can be attached to this area for use
as a cranial window, or it can be used for applying additional adhesive, if desired. For our
experiments, a GRIN lens is attached to a round glass cover slip that is glued under the
opening that is just rostral and to the left of the craniotomy. The lens is lowered into a
separate craniotomy (not visible in this photo) as the head plate is lowered. [15]
It is important that the nose of the mouse is tilted upward for GRIN lens implants
in rostral regions of the brain; otherwise the lens will not fully insert into the brain before
the back of the head plate stops against the upper curve of the skull. To raise the nose so
that the skull is more parallel with the head plate, the height of the bite bar on the
stereotaxic frame can be increased. Likewise, for lateral implants the head should be
tilted to the side to avoid having the head plate hit the upper curve of the skull and stop
before the lens is fully inserted. For slightly lateral implants, this can often be
accomplished by slowly adjusting one ear bar higher than another. However, adjusting an
ear bar to access more lateral positions requires a larger angle and will result in the ear
bar coming out of the ear canal. For these insertions, it will be necessary to adjust the
angle of the stereotaxic arm that holds the probe holder. (Note: Pressure should never be
applied to one side of the head plate to force it to seal completely against the skull as this
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would cause the end of the GRIN lens to move rapidly in an arc through the brain,
damaging a much larger area of tissue than a proper, linear insertion path.) When the lens
is being implanted in one of these special areas, it is best to check the head angle or the
angle of the stereotaxic arm by lowering a head plate without a lens to the skull and
adjusting the angles for implantation before attempting to implant a GRIN lens.
4.2.8

Imaging
After acclimating to the room in their home cage for at least 30 minutes, mice

should be anesthetized in an induction chamber under 3% isoflurane. The heater for the
water reservoir-pump system should be turned on about 20 minutes prior to inducing
anesthesia. When vascular counterstaining is desired, a dye such as Texas Red-Dextran
[123] can be injected via a lateral tail vein [79]. After anesthesia is induced, the mouse
should be placed in the TRIO Platform. Light anesthesia can be maintained using 1%
isoflurane.
Immediately prior to moving the mouse to the microscope, the coverslip should
be cleaned with 70% isopropyl or ethyl alcohol. This cleaning can be done under a
stereomicroscope or large, lighted magnifying glass. Once the window is cleaned, the
TRIO platform and compact anesthesia system are brought to the microscope. The head
plate is positioned under the objective lens of the multiphoton microscope. A fiber optic
light on a flexible metal shaft can be used to illuminate the head plate and glass window
for positioning while using the bright field setting on the microscope. For repeated
imaging in mice with identical head plates, two to three guide bars can be fastened onto
the microscope stage that will automatically position the platform for imaging. We have
not noticed any movement of the platform over imaging sessions as long as 2 hours. The
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platform could be taped into place if procedures are performed during the imaging
session that might move the platform.
To test our system for in vivo, multiphoton imaging, we used GFAP-GFP mice
(The Jackson Laboratory) with an implanted GRIN lens, as described in the surgical
section. Aligning a GRIN lens for imaging was a more rigorous test of our system than
aligning a cranial window. In vivo images were acquired with a VivoTM 2-Photon
Microscopy Workstation (3i). To focus on the implanted GRIN lens, we used a 40X/0.6
NA air objective with a correction collar (Nikon), as previously described (Murray and
Levene, 2012). GFP was excited using a Chameleon multiphoton laser (80 MHz,
Coherent) tuned to 890 nm and emitted light was filtered using a 525/40 nm bandpass
filter (Brightline®, Semrock, Inc.). For some imaging sessions, the vasculature was
stained with Texas red-dextran dye (Life Technologies, Inc.) via a tail vein injection. This
dye was simultaneously excited with the 890 nm laser light used for exciting GFP to
capture images in the green and red channels at the same time. A 612/69 nm bandpass
filter (Brightline® filters by Semrock, Inc.) was used to filter the emission from the red
dye. Scanning was controlled by Slidebook, a proprietary program that controls the (3i,
Inc.) and performs image analysis and processing. We used a 2 µs dwell time with pixel
averaging (4/scan). Power at the sample was adjusted to ~35 mW using a Pockels cell
(Conoptics, Danbury, CT, USA) which was controlled using a Slidebook interface.
4.2.9

Images of TRIO System
Images of the TRIO system were acquired by Kayla Ponder and Teresa Murray,

PhD.
4.3

Results
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4.3.1

Summary of Performance
The TRIO platform in vivo integrated imaging support system (Figure 31) has

been used over 40 times. The rigid base plate provided a sturdy, yet thin base for
positioning and holding a mouse under a microscope objective. The elastomer covering
over the nose cone provided increased collection of anesthesia, lowering the percentages
of anesthetic to induce and to maintain anesthesia. It also greatly reduced or eliminated
any odor of anesthesia in the room, which likely reduced exposure of researchers to the
anesthetic. Additionally, the water channels remained clear and the base and water lines
and connections remained water tight. Furthermore, the restraint system successfully
positioned mice ranging from 25 – 55 g with little or no motion artifact from breathing or
heartbeat. Moreover, the alignment was sufficient for the demanding technique of GRIN
lens imaging in which the laser beam must be parallel to the axis of the lens to image
deep brain tissue optimally.
4.3.2

Base Plate Temperature Distribution
Temperature measurements were acquired by Kayla Ponder and Benjamin S.

Kemp. Temperature measurements were taken at the top of the heated base plate at five
equally-spaced positions in the middle of the assembled plate, starting near the nose cone
where the head of the mouse is placed (Position 1), and ending in the section near where
end of the tail rests on the plate (Position 5). A Fluke 62 mini infrared thermometer
(Fluke, Inc.) was used to make these measurements. Three sets of readings were acquired
over 2 days. The first set was taken on Day 1; the second and third sets were acquired on
Day 2. Prior to making measurements, the water in the reservoir-pump system (300
ml/min flow rate) was heated to 40 ˚C, as measured with an immersible glass laboratory
thermometer. The IR thermometer was checked by measuring the temperature of the
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water bath, which matched the temperature of the immersed thermometer. After this, the
water inlet and outlet tubes were connected to the base plate via Luer lock fittings and
then the circulating pump was turned on. Temperature readings were taken at 5-minute
intervals for the first 30 minutes and 10 minute intervals from 30 to 60 minutes. On Day
2 the water was drained between Test 2 and Test 3 and the plate was allowed to return to
room temperature (about 22 ˚C). The water reservoir remained heated. For Test 2, the
tubes were connected in reversed positions so that the water flowed in the opposite
direction, as summarized below.
Test 1: Flow from nose cone to rear
Test 2: Flow from rear to nose cone
Test 3: Flow from nose cone to rear
Temperature increased slightly over the first few time points before it stabilized.
Therefore, only the last 6 measurements (20 – 60 min.) were used to determine the mean
temperature at each position (Table 31).
Table 31. Mean temperature at top of base plate. SEM is square error of the mean; n=3
measurements for each position [15].

4.3.3

Position
Number

Mean ± SEM (°C)

1

35.1 ± 0.5

2

35.2 ± 0.6

3

35.2 ± 0.6

4

32.6 ± 0.8

5

24.1 ± 0.2

Inducing Anesthesia
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Eight meters of 4-mm ID x 6-mm OD clear polymer tubing carried the heated
water from the heated water reservoir to the platform and back to the reservoir (4 meter
length for each direction). Some heat was lost as the water traveled through the tubing;
thus, it was necessary to maintain the water in the reservoir at 40 ºC to maintain a desired
temperature of 35 ºC on the top of the heated base plate. The length, wall thickness,
diameter, and material composition of the tubing could affect the amount of heat loss, so
future systems with different lengths and types of tubing may require a higher or lower
reservoir temperature.
The large decrease in mean temperature recorded for Position 5 was independent
of the direction of water flow. Thus, the decrease was most likely not related to the loss
of temperature over the distance of the serpentine water channel in the plate. The silicone
coating was thicker over the far end of the plate that included Position 5. This rubberlike,
waterproof coating could serve as an insulator and is the most likely explanation for the
lower temperature in this area. This temperature inhomogeneity did not affect the ability
of the plate to warm a mouse because only the mouse’s tail rests over Position 5.
Anesthesia was induced using 3% isoflurane in an induction chamber connected
to a SomnoSuite IDV gas anesthesia system [124]. A mouse was considered anesthetized
after it ceased attempting a righting response when turned on its back in the chamber. At
this point the mouse was quickly transferred to the nose cone of the support system and
isoflurane anesthesia was maintained at 1.5% for surgery and 1% - 1.5% for imaging
(n>40). We were able to keep the mouse fully anesthetized for over 2 hours, the average
length of our imaging sessions. Routine toe pinches every 15 minutes were performed to
ensure that mice were anesthetized. Furthermore, by using the shroud over the nose cone
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and the activated charcoal scavenging system built into the SomnoSuite® system, we
noticed that the smell of isoflurane was absent or greatly diminished when the shroud was
in place. The reduced odor is consistent with a recent report that predicts a much lower
level of isoflurane gas escaping into the room [124].
4.3.4

Fitting the Platform into a Small Space
The TRIO platform fit under the relatively narrow space of 35 mm between our

microscope objective lens and stage. Although the overall height of our system is 2.7 cm
(Fig 8) from the bottom of the base plate to the top of the head plate holders, the top of
the head plate is held at 2 cm. Thus, the platform can be used in an imaging space only
~2.2 cm high, which means that it can be used on more microscope systems without
replacing the microscope stage. In contrast, the Mouse and Neonatal Rat Adaptor
(Stoelting Co.) was too tall to fit under the microscope objective (Figure 38). The
distance from the objective to the top of the mouse head was about 75 mm, which would
require removal or modification of the microscope stage. Similarly, a mouse placed on an
electrically heated pad (RightTempTM warming pad, Kent Scientific Corp.) or on a
thermal pad (39DP Deltaphase Isothermal Pad, Braintree Scientific, Inc.) had a combined
height that exceeded 35 mm. An alternative would have been to place the mouse under
the objective lens on a thin, electrically heated plate (TCAT-2LV, Physitemp Instruments
Inc.). However, the plate was wide and long and there was no good way to mount the
head plate holder and a nose cone onto it in a secure manner.
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Figure 38. Height comparison. Comparison of the size of the TRIO platform with a
Mouse and Neonatal Rat Adaptor with an electrically heated warming pad. (A)
Anesthetized mice restrained in the two systems. The TRIO system is capable of
warming the entire mouse, but is still much smaller than the Mouse and Neonatal Rat
Adaptor. (B) Close-up image of the two restraint systems. The top of the mouse head in
the TRIO system is 2.2 cm above the table compared to 7.0 cm in the other system [15].
4.3.5

Suitability for In Vivo Microscopy
The support system has allowed us to image successfully multiple mice implanted

with GRIN lenses over several weeks for a total of over forty imaging sessions. The head
plate and holder system held the head securely so that we observed little or no evidence
of motion artifacts in our images. We also did not experience problems with
misalignment of the lens with the laser beam.
Figure 39 is a representative set images of astrocytes in a 50 m thick region of
brain in a live GFAP-GFP mouse. The image set was taken through a 1.1 mm long, 350
m diameter GRIN lens implanted into the prefrontal cortex. Cell bodies and processes
can be seen at all levels through the 50 m z-stack with some depths having more cell
bodies that others. This type of imaging can virtually section the brain at varying depths
and it can be repeated over time in the same animal. Figure 310 is a two-channel image
showing blood vessels and GFP+ glial cells wrapped around a blood vessel.
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Figure 39. In vivo image set of astrocytes in lower levels of cortex viewed through an
implanted GRIN lens. A z-stack of 51 images spaced 1 m apart in depth was acquired
through a GRIN lens implanted in an adult GFAP-GFP mouse. Astrocyte cell bodies and
processes were observed throughout the volume. Z-projections were made of several
consecutive image planes (steps). All images were projections of 5 consecutive image
planes with the exception of Image E in which 10 planes were used for the projection.
The most dorsal image plane was defined as plane 1 and the most ventral image was
plane 51. Z-projection planes for A-H were, as follows: A. 1-5, B. 5-10, C. 10-15, D. 1520, E. 25-35, F. 35-40, G. 40-45, H. 45-50. A Gaussian filter with σ=1.33 was applied to
all channels to reduce background noise. Scale bar = 5 µm [15].

Figure 310. Two-channel in vivo image obtained through an implanted GRIN lens. The
image is from prefrontal cortex of an adult GFAP-GFP mouse implanted with a 350 m
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diameter GRIN lens. Texas red-dextran dye was injected into the tail vein to visualize the
vasculature. A few glial cells expressing GFP under the GFAP promoter can be seen near
one of the blood vessels near the center of the image. A Gaussian filter with σ=1.33 was
applied to all channels to reduce background noise. Scale bar = 5 m [15].
4.3.6

Summary of Results
We have developed a low profile, multifunctional, in vivo brain imaging support

system capable of positioning a mouse in precise alignment with an upright microscope,
while simultaneously providing heat and anesthesia. The system is easily assembled and
has a small footprint.
4.4
4.4.1

Discussion

Advantages of 3D Printing
The use of 3D printing is a relatively inexpensive manufacturing process in both

time and material costs. The method is also flexible; typically one need only make a
dimensional change in a design program, such as SolidWorks®, to modify the prototype
for supporting a rat or other laboratory animal. The head plate can be redesigned and
repurposed if the region of interest is along the spine.
4.4.2

Future Construction and Designs
In a few instances, a mouse’s head plate became entangled in the overhanging

bars that form the food hoppers in its cage. This resulted in head plates being dislodged.
We now use a cage system without low overhanging bars to avoid this problem. Future
head plate modifications will include reducing the size of the head plates so that they do
not become caught between cage bars.
We have also determined, through measuring the mean temperatures of the base
plate surface across the length of the plate that the silicone adhesive applied to seal the

74
heated plate also acts as an insulator when applied in a sufficiently thick layer. The area
with a relatively thick layer of silicone had a consistently lower temperature that was not
dependent on the directions of warm water flow through the plate. This was not a
problem for warming our mice because only the tail rested on this area. For future
systems, a method to apply a uniformly thin coating of silicone (< 1mm) should be
developed. Alternatively, the top plate might be effectively fused to the bottom section of
the base plate using heat, as mentioned above.
4.4.3

Potential Impact
Currently, a variety of different components are combined to create a support

system for in vivo optical imaging of anesthetized mice. Many of these systems include
custom made components. Furthermore, some systems include custom stages that may be
necessitated by the relatively large size of some components. Taken together, these
conditions can make it difficult for other researchers to replicate these systems and make
use of techniques that others have developed. We have combined the functions of head
restraint, alignment, warming and anesthesia into one low-profile, compact system.
Because the system is small, it should work on a wider range of confocal and multiphoton
microscope systems than other larger systems. We hope that this system or one similar to
it will provide a more standardized means of conducting these types of imaging
experiments and thus, enhance repeatability. Moreover, we hope that this system will
enable more labs to conduct in vivo optical imaging experiments.
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CHAPTER 5
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CHAPTER 6
IN VIVO IMAGING DEVICE FOR MCAO
AND THERAPY DEVELOPMENT
6.1

Ischemia/Reperfusion

Following ischemia, a decrease in oxygen causes a depression in cell signaling.
The sodium-potassium channels are damaged, allowing the influx of calcium ions. As a
result, an increase of glutamate is released, leading to excitotoxicity. As the neurons
depolarize, more calcium enters the cells, releasing more glutamate and thus, magnifying
the initial injury. Additionally, approximately 4-6 hours following injury, the blood brain
barrier breaks down, directly affecting the brain vasculature. As a result of the neuronal
and vasculature damage, genes become activated leading to the release of cytokines,
activating microglia, and increasing inflammation [125].
Once the neurons become damaged, they display proteins, labeling them for
destruction. The proteins attract de-ramified microglia, which in turn phagocytose the
affected neurons [125], leading to a loss in the parenchyma volume that subsequently
leads to neuronal deficits. While the microglia are important for neuronal pruning in
growth and for clearing dead cells in the necrotic region after a stroke, they can
phagocytose damaged, but viable neurons following injury. As a result, it may be
beneficial to prevent microglia from phagocytosing cellular material in the early stages of
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ischemia [126]. In order to effectively find treatments, the role of microglia following
injury needs to be better defined.
Microglia have been shown to become activated beginning at 6 hours post
reperfusion and become fully activated with an amoeboid shape peaking at approximately
72 hours post reperfusion [45]. The change to an activated state causes the microglia to
retract their processes, increasing their cell soma area. This mechanism allows them to
become mobile and phagocytose damaged material, including other brain tissue and
vasculature [127]. Research has suggested microglia contribute to the breakdown of the
blood brain barrier following ischemia [128], [129]. Cross staining has shown the
presence of blood vessel material in the intracellular region of microglia as well as
microglia enwrapping the blood vessels [66].
To further demonstrate the role of microglia in ischemia, studies conducted on
mice devoid of microglia showed beneficial outcomes following reperfusion [130], [131].
The volume of damage was less significant and blood flow was more prominent in the
penumbra. This data suggests a decrease in the activation of microglia may be
therapeutically beneficial. While evidence has indicated that down regulation of
microglia is beneficial, if the area is completely devoid of these cells, other damage may
occur. Microglia are needed for daily housekeeping in the brain. Taken together, a
balance of microglia activation may be needed to optimize therapeutic benefits.
When stroke occurs chemokines and cellular adhesion molecules (CAM) are
expressed. As a result, leukocytes to migrate into the damaged tissue. Additionally,
resident microglia become activated, leading to excessive inflammation. The
inflammation causes endogenous strategies involving the glucocorticoid regulated

78
protein, annexin A1 (AnxA1) to be initiated by the immune cells. AnxA1 modulates the
inflammatory response by targeting the formyl peptide receptor 2 (FPR2); this was
demonstrated by the administration of a known antagonist, Boc2. When Boc2 is
administered simultaneously with AnxA1, the anti-inflammatory properties of AnxA1
were negated [98]. When exogenous AnxA1 was administered to animals undergoing
ischemia/reperfusion injury, leukocyte adhesion and rolling was significantly decreased,
reducing the inflammatory response normally seen in this disease model [96], [100].
AnxA1 is endogenously expressed in microglia and it has been demonstrated, in
vitro, that exogenous AnxA1 controls the phagocytosis of apoptotic neurons and
promotes the resolution of inflammatory microglial activation. This demonstrations that
AnxA1 has a fundamental role in brain homeostasis and the administration of exogenous
AnxA1 may be potentially affective as a therapeutic for neuroinflammation [101] .
To date, only one clinically relevant therapeutic exists for stroke, and it is only
beneficial in about 5% of stroke cases [10]. Therefore, the pursuit of new therapeutics
remains a priority. Previous research has shown that exogenous AnxA1 was beneficial in
animal models of post-ischemia/reperfusion [96], [98], [100], and that it had a protective
effect against inflammatory microglia in vitro [101]. To build upon these preliminary
findings and determine the effect of AnxA1 in the subcortical regions of the brain, mice
with fluorescently labeled microglia were given AnxA1 at 6 and 18 hours post
reperfusion and microglia dynamics were measured in vivo through implantable
micro-lenses and multiphoton microscopy.
6.2
6.2.1

Lens Implantation

Materials and Methods
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Mice were briefly anesthetized with 5% isoflurane and subsequently given an
intraperitoneal injection of ketamine/xylazine cocktail (10 mg/kg ketamine and 1 mg/kg
xylazine in 0.9% sterile saline) and transferred to a stereotaxic frame (Stoelting Co.,
Wood Dale, Illinois, USA), equipped with ear bars and a nose cone for isoflurane
delivery (Leica Biosystems. Inc., Buffalo Grove, Illinois, USA). A SomnoSuite® system
(Kent Scientific, Torrington, Connecticut, USA) was used to control isoflurane delivery.
Throughout surgery, anesthesia was maintained with 1.0%-1.5% isoflurane. To ensure
the animal was fully anesthetized, toe pinches were performed every 15 minutes. Aseptic
surgical techniques were used to create a midline incision and remove the periosteum
with a surgical bone scraper. A micro drill with a 0.5 mm dental burr was used to make a
1 mm craniectomy in the right hemisphere of the cortex and the dura was removed with
the tip of a 28 G hypodermic needle at a low angle to the dura[14], [15]. Each lens
implant consisted of a 500 m diameter, 1.7 mm long, just under ½ pitch, ILH, uncoated
GRIN lens (Go!Foton, Somerset, New Jersey, USA) affixed to a #1.5 glass 3 mm
diameter cover slip (Electron Microscopy Sciences, Hatfield, Pennsylvania, USA) using
NOA 71 optical adhesive (Norland Products, Inc., Cranbury, New Jersey, USA), as
previously described. [14], [78] The cover slip facilitates lens handling and serves to
correct for some of the spherical aberration inherent in GRIN lenses [78]. A small
stainless steel washer, 1 mm thick, was permanently affixed to the cover slip. The washer
was mounted in a cannula holder for stereotaxic insertion of the lens. The cannula holder
was angled 15° toward the midline and the lens was implanted 0.9 mm rostral to bregma,
2.25 mm lateral to the midline, and lowered to a depth of 1.3 mm at a rate of 0.1 mm/min
into the cortical penumbra region. The implant was secured to the skull with dental
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adhesive (RelyX, 3M Corp) which was allowed to set for 15 minutes before the cannula
insertion tool was disconnected. This procedure immobilized the lens and sealed the
craniectomy. After removing the insertion tool, a rigid plastic head plate was aligned to
the washer and attached with cyanoacrylate (Krazy Glue®). The head plate was custom
designed and 3D printed in-house for use with our TRIO platform imaging support
system, which is also 3D printed in-house [15]. Mice were returned to their cages with a
warm heating pad (Braintree Scientific, Inc., Braintree, Massachusetts, USA) and were
monitored until they maintained an upright posture. To minimize post-surgical pain, an
analgesic was dissolved in the animal’s water (Children’s Ibuprophen, 30 mg/kg/day in 8
oz of water) for 72 hours following the procedure. Mice were allowed to recover at least
three weeks before imaging [14].
6.2.2

In Vivo Imaging
Mice were briefly anesthetized with 5% isoflurane and then transferred to a TRIO

platform imaging support system, as previously described [15]. Anesthesia was
maintained throughout the imaging session with 1.5% isoflurane. A Chameleon Vision-2
multiphoton laser (80 MHz, Coherent) tuned to 1020 nm was used to excite tdTomato
fluorescence. Emitted light was filtered through a 612/69 nm bandpass filter (Brightline®
filters, Semrock, Inc). Scanned images were acquired on a custom, upright, multiphoton
microscope system, equipped with a Pockels cell and GaAsP detectors (Intelligent
Imaging Innovations, Inc., Denver, Colorado, USA), a 40x/0.6 NA objective with a
correction collar for up to 2 mm of glass (Nikon Instruments, Inc., Japan) [78] and
Slidebook 6 software (3i, Inc.). A pixel dwell time of 2 µs was used with pixel averaging
(5/scan) to acquire three-dimensional (z-stack) images composed of 61 images with a
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1 m step size. Baseline images were acquired at least three weeks after lens
implantation and one week prior to the MCAo procedure. Post-treatment images were
acquired 20 – 24 hr after the procedure. Image sets were exported and stored as TIFF
files on an external hard drive for offline analysis.
6.2.3

Middle Cerebral Artery Occlusion
Mice underwent sham (n = 1) or transient (60 minute) middle cerebral artery

occlusion (MCAo) (n = 8) induced by the occlusion of the right middle cerebral artery
using an intraluminal filament method, as previously described [96]. MCAo was
conducted by Dr. Felicity Gavin’s lab at LSUHSC.
6.2.4

Annexin A1 Treatment Protocols
Animals were randomly assigned to a treatment group and were given either

saline (n=2), AnxA1 (n=4), or AnxA1 + Boc2 (antagonist) (n=2) intravenously.
Treatment was administered by Dr. Felicity Gavin’s Lab at LSUHSC-Shreveport, and
mice were transferred to Louisiana Tech University for imaging.
6.2.5

Perfusion and Fixation of Brain Tissue
Within 1 – 3 hr of post-procedure imaging, mice were deeply anesthetized with an

intraperitoneal injection of a ketamine (10 mg/kg)/xylazine (1 mg/kg) solution. After
deep anesthesia was confirmed with noxious toe pinches, mice were transcardially
perfused first with phosphate buffered saline (PBS) until blood was cleared and then with
20 ml of cold (4 °C), 4% paraformaldehyde solution, 7.2 pH (PFA) [14]. Heads were
decapitated and then post-fixed in PFA overnight. Next, lenses were removed from the
brain and then brains were removed from the skull [14]. After removal, brains were
immersed in PBS with 30% sucrose in preparation for cryosectioning.
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6.2.6

Sectioning and Mounting
Whole brains were transferred to our collaborator, Dr. Xiao Hong Lu, at

LSUHSC-Shreveport for sectioning. Once sectioned, slices were returned to our lab for
mounting, imaging and image analysis. The slices were mounted onto slides for imaging
by Benjamin S. Kemp and Kayla Ponder in Dr. Teresa Murray’s lab at Louisiana Tech
University.
6.2.7

Slice Imaging
Mounted tissue slices were imaged by Benjamin S. Kemp and Kayla Ponder.

Scanned images were acquired using the same MPM system as described in Section
4.2.2. A pixel dwell time of 2 µs was used with pixel averaging (5/scan) to acquire three
dimensional (z-stack) images composed of 31 images with a 1 m step size. Three brain
slices for each animal were imaged in order to obtain averaged results. Six regions of the
brain slice were imaged in order to determine if the effects of MCAo and AnxA1
treatment differed with location. The positions included: A) CA3 in the hippocampus, B)
the cerebral cortex directly above CA3, C) the necrotic core of the ischemic region, D)
the transition zone, directly above position C on the ventral side of the corpus callosum,
E) penumbra of the stroke, and F) the rostral cortex (Figure 41).
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Figure 41. Nissl stained sagittal section (image, exclusive of locations for analyzing
microglia activation levels, courtesy of Dr. Xiao Hong Lu, Louisiana State University
Health Sciences Center, Shreveport, LA). Locations for analysis of microglia activation
state in brain slice images were, as follows (A) CA3 in the hippocampus, (B) the cerebral
cortex directly above CA3, (C) the necrotic core of the ischemic region, (D) the transition
zone, directly above position C on the ventral side of the corpus callosum, (E) penumbra
of the stroke, and (F) the rostral cortex.
6.2.8

In Vivo Image Analysis
Image analysis was performed by persons blinded to the treatment condition.

ImageJ (version 1.51i) [132] was used to identify and calculate the soma area of each
fluorescently labeled microglial cell. The region of interest tool was used to draw and
record the outline of each soma. The largest area of each soma was located by evaluating
each image plane in the z-stack. The threshold tool was used to subtract the background
fluorescence in this selected plane and to assist in identification of microglial processes
[133]. The measurement tool was used to create a spreadsheet of the area of each soma.
The mean value and standard error of the mean of the soma area were calculated for each
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mouse for pre- and post-treatment conditions. Data were normalized to the baseline
values.
6.2.9

Brain Slice Image Analysis
Image analysis was performed by persons blinded to the treatment condition.

ImageJ (version 1.51i) [132] was used to identify and calculate the area of each
fluorescently labeled microglia cell. Max intensity z- projections of 31 x 1 µm were
created for each animal. Brightness and contrast were adjusted to visualize individual
cells. The region of interest tool was used to draw and record the outline of each soma
and draw a line across the longest part of the cell body to serve as the cell diameter. The
Sholl’s analysis plugin [134] was used to determine additional properties indicating
microglia activation state. Shells were defined with a starting radius of 10 µm, and the
ending radius of the cell was determined by the user. The radius step size for the
concentric circles was 5 µm. The number of primary branches was manually entered for
each shell and linear profile with a best fit profile was used. The results were exported as
an Excel file (Microsoft Corp.) and the average results for soma area and the ramification
index for each animal were tabulated and used for comparison.
6.3
6.3.1

Results

Properties of Annexin A1
Animals underwent MCAo or sham surgery and received either saline, AnxA1, or

AnxA1 + Boc2 (antagonist). Images were acquired before and 24 hours after MCAo in
the subcortical regions of the brain and normalized cell soma area was compared (Figure
42). Because the number of animals was low, no statistical difference was found as
compared to the control animal, although based on the results, it appears AnxA1
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treatment may exhibit protective properties post-I/R (Figure 43). I/R-AnxA1 normalized
average cell soma area was consistent with the normalized sham-vehicle treated animal
(1.07 ± 0.07 versus 1.09). I/R-AnxA1 + Boc2 and I/R- AnxA1 had comparable
normalized results, 1.08 ± 0.01 and 1.07 ± 0.07, respectively, suggesting that the
FPR2/ALX mechanism may not be involved in modulating microglia activation post-I/R
in subcortical regions of the brain.

Figure 42. Representative images at baseline and 24 hours after sham or transient (60
min) MCAo procedure. Insets are single cells showing activation states. Microglia
become activated (retracted processes) (B) as compared to both baseline (A, C) and sham
treated animal (D). Insets are representative images of microglia morphology. Images are
z-projections of 10 x 1 µm slices. Scale bar = 10 µm.
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Figure 43. AnxA1 may be protective against microglial activation, but not through
FPR2/ALX mechanism. Mice underwent sham (n=1) or transient (60 min) MCAo (n = 8)
and administered saline (n=2), AnxA1 (n=3) or AnxA1 + Boc 2 (n=2). Cell soma area
was calculated at baseline and at 24 hours post reperfusion. Data is represented as mean
normalized soma area ± SEM.
6.3.2

AnxA1 in the Cortex and Necrotic Core
Post-mortem brain slice analysis was conducted to determine if AnxA1 exhibited

protective effects throughout the brain and was not limited to the area under the lens.
Brain slices were imaged and cell soma area was averaged for each animal and compared
to determine the extent AnxA1 modulates inflammation in each position (Figure 44).
While the number of animals was not sufficient to determine statistical significance and
to draw conclusions, it appears AnxA1 may be protective in the cortex (Figure 45).
Larger soma areas, a property of microglia activation, were measured in the saline treated
group as compared to the AnxA1 treated animals. Furthermore, Boc2, the antagonist, was
not effective as this time point.
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Figure 44. Representative brain slice images of positions B, E, and F comparing
microglia activation when treated with AnxA1 (A-C) versus treated with saline (D-F).
AnxA1 treated animals had microglia with smaller soma areas in the cortex after MCAo.
Insets are representative, enlarged images of microglia morphology. Scale bar = 15 µm.

Figure 45. AnxA1 potentially has protective effects in the cortex. At 24 hours post I/R,
AnxA1 treated mice tended to demonstrate modulated inflammation, indicative by
smaller soma areas as compared to saline treated animals, but not through the FPR2/ALX
mechanism as the antagonist, Boc2, did not appear to be effective.
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While Annexin A1 exhibited protective effects in the cortex, it did not appear to
be as affective in the hippocampus, as cell soma areas in the treated groups were
comparable to the saline treated animals. Furthermore, when the antagonist was
administered, it was not affective at this time point. (Figure 46, Figure 47).

Figure 46. Representative brain slice images from position A (hippocampus) comparing
microglia activation when treated with AnxA1 (A) versus treated with saline (B).Insets
are representative up close images of microglia morphology. Scale bar = 15 µm.

Figure 47. AnxA1 does not exhibit protective properties in the hippocampal region.
Saline and AnxA1 treated animals exhibited comparable cell soma areas.
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Interestingly, AnxA1 modulated inflammation, as shown by smaller cell soma
areas, in the ischemic core (Position C) and the transition zone (Position D), regions
containing irreversible damage and widespread cell death (Figure 48, Figure 4-9).
Consistent with other regions, the antagonist was not affective at this time point.

Figure 48. Representative brain slice images of position C (A, C) and position D (B, D),
the necrotic core and transition zone, respectively. Cell soma areas in the AnxA1 treated
animals exhibited cells with resting morphology. Insets are representative images of
microglia morphology. Scale bar = 15 µm.
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Figure 49. AnxA1 modulates microglial activation in the ischemic core (position C) and
transition zone (position D). Treated animals exhibited smaller soma areas in both
positions. The antagonist, Boc2, was not effective in these regions and time point.
6.3.3

Imaging System for MCAo
While the study conducted did not lead to statistically significant conclusions

concerning the use of AnxA1 as a therapeutic, it did demonstrate the exciting potential to
use GRIN lens imaging as a tool to identify microglial activation, a hallmark of
neuroinflammation, post-MCAo and to evaluate potential therapeutics in an in vivo
model. The imaging device was implanted to collect images in subcortical regions of the
mouse and the normalized data gave comparable results to position E, the penumbra
(Figure 4-1). The nature of the methodology allowed each animal to act as its own
control, reducing the number of animals needed for the study. Baseline, three
dimensional images were acquired prior to MCAo for each mouse and the data were
normalized to post injury results, reducing the inter-animal variability seen in traditional
histological analyses.
6.4

Discussion
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With stroke being a prevalent problem with minimal existing interventions, it is
imperative we find new therapies. Annexin A1 has previously been shown to modulate
the inflammatory response in ischemia/reperfusion by reducing the number of rolling and
adherent leukocytes through the FPR2/ALX mechanism of action [98]. While the number
of animals in this preliminary study was too small for statistical inference, the in vivo data
suggest that Annexin A1 has the potential to modulate microglia activation postreperfusion in the penumbra region of the brain. However, it does not appear that the
modulation is acting through the FPR2/ALX mechanism. Histological examination of the
brains showed Annexin A1 may be effective in protecting the cortex post I/R, but not the
hippocampus. Additionally, it appeared to have an effect on the cells located in the
necrotic core, an area that typically has irreversible damage. Without more mice, it is
difficult to definitively say where Annexin A1 is exhibiting a protective effect and the
mechanism involved.
The novel imaging method used in the study was able to collect quality images of
microglia and cell soma area could be normalized to the baseline, reducing inter-animal
variability. Additionally, it showed results consistent to brain slice analysis,
demonstrating it as an effective tool for monitoring microglia activation in the MCAo
model and assessing the effectiveness of potential therapeutics.
6.5

Future Work

To obtain more conclusive results about the effectiveness of annexin A1 as
microglia modulator, more animals are needed. This study set the ground work and
confirmed GRIN lenses are an effective technology for the MCAo model of
ischemia/reperfusion by identifying microglial activation 24 hours post injury, and it
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showed annexin A1 may be protective in the cortex and ischemic core. Now, a more indepth study is needed to confirm the effectiveness of the endogenous drug.
A benefit of this novel imaging tool is the ability to collect longitudinal data.
Imaging windows can be extended out days and even months after the initial injury and
microglial dynamics can be measured over time. This imaging tool makes it possible to
collect data immediately following injury and during the recovery phase to better
understand not only how microglia dynamics change when therapeutics are administered,
but the fate of the microglia when therapeutic administration is stopped in the same
mouse. This capability not only reduces inter-animal variability but also minimizes the
number of animals used. Overall, GRIN lens technology has shown exciting potential to
be used as a preclinical research tool and will lead to a better understanding of brain
injuries.

CHAPTER 7
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CHAPTER 8
LONGITUDINAL IN VIVO IMAGING SYSTEM
FOR A MURINE MODEL OF TRAUMATIC
BRAIN INJURY
8.1

Diffuse Axonal Injury

The human brain can be described as viscoelastic, and it can tolerate the gradual
accelerations associated with normal, daily living. With slowly applied forces, the brain
tissue is ductile and can recover its original geometry unscathed [7]. When a force is
rapidly applied (< 50 ms), the brain acts like a more brittle solid, resulting in shearing of
the cell membrane and cytoskeleton, followed by a delayed elastic return to its pre-injury
state. The injury is further intensified if the force applied surpasses the threshold of the
axons [135]. As a result, axon damage is dependent on the rate and the magnitude of
strain during a TBI.
The most common closed head injury to occur is known as diffuse axonal injury
(DAI), which results in subtle, but significant widespread damage throughout the brain
parenchyma and primarily affecting the corpus callosum, the communication lines
between the two hemispheres of the brain. These progressive changes are a direct
consequence of the primary mechanical forces at the time of injury. Characteristics of this
injury were experimentally detected as early as 1943 by Holbourn et al., who used gelatin
molds of brain sections and found that rotational forces caused shear and tensile strains
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throughout the material [136]. Morphological alterations in white matter were
histologically found in severely injured TBI patients and it was proposed that the shear
strains at the moment of injury were responsible for the damage [137]. Furthermore, the
axons exhibited swollen profiles in the moderate to severe range of injury [138].
While immediate disconnection of axons is seen in severe brain injury, the major
damage of DAI is secondary axon disconnection which occurs over a prolonged period of
time. As a result of mechanical forces, the axonal cytoskeleton breaks down, becoming
twisted and misaligned, leading to secondary physiological changes such as interrupted
axonal transport, periodic swellings along the axon, and in some cases neurodegeneration
[135]. The injury not only causes changes on a cellular level, but also leads to a
disruption in cognition and behavior, resulting in poor outcomes for the patient [39],
[139]. Therefore, it is necessary to not only better understand the progression of axonal
damage, but also identify potential therapeutics to mitigate secondary damage.
8.1.1

Undulations
Microtubules represent the stiffest component of the axon and are made of stable

and dynamic tubulin polymers. The dynamic portions of microtubules allow a rapid
change in length during axonal development and regeneration [140]. Conversely, this
trait of axons may make them more susceptible to mechanical trauma seen in diffuse
axonal injury.
Cultured axon models have been developed to observe the pathologies seen in in
vivo traumatic brain injury. A threshold for primary axotomy and temporal evolution of
axon response to stretch injury was investigated and it was found that primary axotomy
did not occur for strains under 65% and in fact, strains of 77% did not sever all axons.
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Rather, it was discovered that some axons could stretch beyond their original length, but
upon relaxation would develop areas with the geometry of half circles or triangles, known
as undulations. While some axons developed these undulations, other axons were able to
return to their pre-stretch state, elastically recovering. The data suggest that the distortion
is nonuniform following dynamic stretch injury [141].
In another in vitro study, axons were cultured and subjected to either a slow or
rapid loading condition. Under a slow loading rate, the axons were able to easily tolerate
being stretched two times their original length. However, when rapid loading conditions
were applied (<50 ms), axons consistently showed undulating areas after stretch injury.
After approximately 40 minutes, the axons returned to their pre-stretched state, but an
accumulation of transport proteins formed into areas of swellings. The results of the study
suggest mechanical failure occurs along the microtubules at the time of injury and
microtubules may fail to realign, leading to a physical blockade impeding natural axon
relaxation and the formation of undulations [142].
8.1.2

Axonal Varicosities
One of the identifying features of DAI are periodic axonal swellings resulting

from the accumulation of axonal proteins following microtubule breakage. These
swellings are known as axonal varicosities and appear along the length of a damaged
axon. In an in vitro model, modeling the mechanical loading experienced by neurons in
vivo, the neurofilament structure changes following a stretch injury, interrupting the
transport of material to the cell soma [141]. The accumulation of proteins in these
swollen areas is a key feature of damage and disruption of axonal transport.
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In animal models, amyloid precursor protein (APP) is commonly used, with high
sensitivity, as a biomarker for DAI. APP is one of the proteins that accumulates rapidly
and causes areas of swelling within 2 hours of injury. APP was detected even 30 days
following initial injury, suggesting not only axonal transport is impaired, but that this
damage is long term [143]–[145].
Neurofilament is a key component of the axonal cytoskeleton. Its accumulation
has also been found in areas of swelling [146], [147], demonstrating that damaged
neurofilaments play a role in the development of varicosities. Neurofilament compaction,
which is the reduction in the interfilament spacing caused by the breakdown of side arms,
contributes to the blockade of axonal transport. In vitro studies have shown that,
following axonal stretch injury, both microtubule and neurofilament damage correlated
with undulations and within hours of the injury developed into varicosities [148].
To date, the evidence found concerning the development of varicosities has been
limited to histopathological examination of post-mortem brain tissue or in vitro models.
In order to better understand the development and fate of this post-TBI feature,
longitudinal in vivo analysis is needed.
8.1.3

Axonal Bulbs
A widely recognized, but not necessarily more common pathology discovered

after DAI is the presence of large single swellings known as axonal bulbs. Primary
axotomy is rare event, but secondary axotomy, the weakening of the axons by
undulations and axonal varicosities, occurs over the course of hours to days, and in some
cases months following the injury [7], [36]. Not all injured axons will develop into axonal
bulbs. In fact, many axons are able to become undulated, develop varicosities, recover
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and return to their relaxed state. While the mechanical damage cannot be reversed, the
recovery phase offers an opportunity to intervene with a therapeutic.
8.2

Minocycline as a Treatment for Traumatic Brain Injury

Minocycline has been effective when administered acutely following traumatic
brain injury. It limits both early and chronic neuroinflammation and preserving the
integrity of the brain [91], [92]. Additionally, the drug has shown promise in protecting
long term behavioral and functional outcomes, which are negatively impacted by
traumatic brain injury [93]. While minocycline cannot prevent the early effects of
mechanical damage, such as the accumulation of β-APP [91], long term it protects the
volume of high populated axonal areas, such as the corpus callosum, suggesting the drug
is preventing axonal loss which can occur after undulations, varicosities, and terminal
bulb formation.
8.3

Longitudinal Data Need

Longitudinal data are needed to better understand the time course of axonal
damage after traumatic brain injury and the mechanism by which treatments, such as
minocycline, intervene and protect the brain. Additionally, while minocycline was
effective when administered acutely, it is not always possible to treat individuals early on
following injury. Therefore, it is necessary to determine if the drug has protective effects
at later time points and if the protection is comparable to early administration.
To date, evidence demonstrating the progression of axonal damage following
traumatic brain injury has been limited to histology, in vitro, and in silico models. While
these methods have added a plethora of knowledge about defining features of diffuse
axonal injury, how these features progress in vivo is still unknown. Thus, to better
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understand the progression from the time of injury to the formation of a terminal bulb,
being able to track the same injured axon longitudinally is imperative. Fortunately, the
technology exists to visualize the time course of DAI. Gradient refractive index (GRIN)
lenses offer an opportunity to collect longitudinal data with high cellular resolution. In
addition to understanding the progression of DAI, it is also important to understand how
potential therapeutics for DAI are affecting axon degeneration. Minocycline was
protective against white matter degeneration and microglia activation following traumatic
brain injury when acutely administered [91], [94], [131], [149].
To further facilitate these investigations, the current study uses a novel imaging
method in which Thy1-YFP mice are imaged in a longitudinal manner, before and
periodically over the course of 30 days following fluid percussion injury (FPI) in mice.
FPI is a model of diffuse brain injury. To demonstrate the utility of this novel imaging
method for preclinical trials, minocycline was administered at a known therapeutic
window commencing at 45 minutes post injury [89]. Additionally, minocycline was
administered to a group of mice commencing at 72 hours post-FPI to determine its
therapeutic potential in a wider treatment window. As a result, progressive axonal
damage and the effect of the potential therapeutic was successfully identified.
GRIN lenses were implanted just above the external capsule in Thy1-YFP
transgenic mice (Figure 5-1). Thy1-YFP mice express yellow fluorescent protein in
motor and sensory neurons that is a strong marker for axons. Following at least three
weeks after GRIN lens implantation, multiphoton microscopy is used to collect baseline
images for each mouse in the study. Once a baseline image is collected, FPI is used to
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induce diffuse brain injury. Images were taken at 1 hour, 3 days, 7 days, 14 days, 30 day,
and 60 days following injury in order to evaluate progressive axonal damage.

Figure 51. A GRIN lens (gray rectangle) is implanted just above the external capsule
(red circle) in order to image axonal damage over time. Adapted from Paxinos and
Franklin, 2012.
To determine if the implanted imaging device is an effective tool for preclinical
trials, a clinically relevant drug was administered. Minocycline, an FDA-approved
antibiotic, has mitigated some of the effects of diffuse brain injury when administered
between 45 minutes and 4 hours following injury [89]. Serving as the positive control in
the experiment, minocycline (45 mg/kg) was administered at 45 minutes following
injury. In order to experimentally determine if minocycline had positive outcomes at a
later time point, since it is not always possible to treat individuals immediately following
injury, minocycline was administered at 72 hours following injury. Subsequent doses, as
done in previous trials [89], were administered at 24 hours and 48 hours following the
initial doses at both the 45 minute and 72 hour time point.
In order to relate structural changes to behavioral changes and further characterize
the effect of the minocycline, the rotarod, neurological severity score (NSS), open field,
novel object recognition, and tail suspension tests were used. The rotarod and NSS tests
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were conducted within the first week (Days 2, 5, and 7) following injury to insure the
animal maintained a diffuse brain injury. The open field, novel object recognition, and
tail suspension test are conducted on Day 60 to test for anxiety, memory, and depression,
respectively. Immediately following behavioral studies at Day 60, animals were perfused
to prepare for histological analysis. A summarized timeline for the experiments can be
found in Figure 5-2.

Figure 52. Experimental Timeline.
8.4
8.4.1

Materials and Methods

Lens Implantation
Mice were briefly anesthetized with 5% isoflurane and subsequently given an

intraperitoneal injection of ketamine/xylazine cocktail (10 mg/kg ketamine and 1 mg/kg
xylazine in 0.9% sterile saline) and transferred to a stereotaxic frame (Stoelting Co.,
Wood Dale, Illinois, USA), equipped with ear bars and a nose cone for isoflurane
delivery (Leica Biosystems. Inc., Buffalo Grove, Illinois, USA). A SomnoSuite® system
(Kent Scientific, Torrington, Connecticut, USA) was used to control isoflurane delivery.
Throughout surgery, anesthesia was maintained with 1.0%-1.5% isoflurane. To ensure
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the animal was fully anesthetized, toe pinches were performed every 15 minutes. Aseptic
surgical techniques were used to make a midline incision, and a surgical bone scraper
was used to remove the periosteum. A micro drill and 0.5 mm dental burr were used to
make a 1 mm craniectomy over the right hemisphere of the cerebral cortex and the tip of
a 28 G hypodermic needle was used, at a low angle to the dura, to remove the dura mater.
[14], [15]. Each lens implant consisted of a 500 m diameter, 1.7 mm long, just under ½
pitch, ILH, uncoated GRIN lens (Go!Foton, Somerset, New Jersey, USA) affixed to a
500 µm diameter, 0.6 mm long custom made glass window. NOA 71 optical adhesive
(Norland Products, Inc., Cranbury, New Jersey, USA) was used to glue the window and
lens to a #1.5 glass 3 mm diameter cover slip (Electron Microscopy Sciences, Hatfield,
Pennsylvania, USA) as previously described [14], [78] The cover slip facilitates lens
handling and serves to correct for some of the spherical aberration inherent in GRIN
lenses [78]. The same adhesive was used to permanently affix a small, stainless steel
washer, 1 mm thick to the cover slip (Figure 53). The washer was mounted in a cannula
holder for stereotaxic insertion of the lens. The cannula holder was angled 15° toward the
midline and the lens was implanted 0.9 mm rostral to bregma, 2.25 mm lateral to the
midline, and lowered to a depth of 1.5 mm at a rate of 0.1 mm/min so that it was
implanted just above the corpus callosum. The implant was secured to the skull with
dental adhesive (RelyX, 3M Corp) which was allowed to set for 15 minutes before
disconnecting the cannula insertion tool. This procedure immobilized the lens and sealed
the craniectomy. Mice were returned to their cages with a warm heating pad (Braintree
Scientific, Inc., Braintree, Massachusetts, USA) and were monitored until they
maintained an upright posture. To minimize post-surgical pain, an analgesic was

102
dissolved in the animal’s water (Children’s Ibuprophen, 30 mg/kg/day in 8 oz of water)
for 72 hours following the procedure. Mice were allowed to recover at least three weeks
before imaging [14].

Figure 53. GRIN lens fabrication. Each implantable lens has 600 µm x 500 µm glass
window and a 1.7 mm long GRIN lens glued to a #1.5 3 mm in diameter glass window.
These lenses were affixed to a 1 mm thick stainless steel washer.
8.4.2

Head Plate Construction
Head plates were designed in SolidWorks software and then 3D printed in house

from PLA filament. The head plates were designed to secure the animal’s head while
imaging such that the GRIN lens was normal to the laser beam. If the GRIN lens is tipped
with respect to the laser beam, the image quality degrades. The head plate is 20 mm x 11
mm x 1 mm (L x W x H) and has a cut out for the washer portion of the GRIN lens
components. (Figure 54A). The back end of the head plate is open to allow an injury hub,
a vital part of the fluid percussion injury system, to be attached during a second surgery
(Figure 5-4B).
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Figure 54. Head plate construction was adapted to allow access to the craniectomy (A) in
order to attach the injury hub during the fluid percussion injury surgery (B).
8.4.3

Head Plate Attachment
Head plates were attached two weeks post GRIN lens implant. Gel cyanoacrylate

(Loctite ®) was used to attach the head plate. The animal was briefly anesthetized with
5% isoflurane and transferred to a stereotaxic frame (Stoelting Co., Wood Dale, Illinois,
USA), equipped with ear bars and nose cone for isoflurane delivery. For the duration of
head plate attachment, isoflurane was maintained at 1.5%. The head plate is carefully
placed so that it is lined up with the washer portion of the lens. Once it is successfully
aligned, additional gel cyanoacrylate (Loctite ®) is placed around the edges of the head
plate to firmly secure the head plate. The cyanoacrylate is allowed to dry for 20 minutes
before the animal is returned to its cage. The head plate remains attached for the duration
of the experiment.
8.4.4

Imaging
Mice were briefly anesthetized with 5% isoflurane and then transferred to a TRIO

platform imaging support system, as previously described [15]. Anesthesia was
maintained throughout the imaging session with 1.5% isoflurane. A Chameleon Vision-2
multiphoton laser (80 MHz, Coherent) tuned to 890 nm was used to excite YFP
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fluorescence. Emitted light was filtered through a green fluorescent protein filter
(Brightline® filters, Semrock, Inc). Scanned images were acquired on a custom, upright,
multiphoton microscope system, equipped with a Pockels cell and GaAsP detectors
(Intelligent Imaging Innovations, Inc., Denver, Colorado, USA), a 40x/0.6 NA objective
with a correction collar for up to 2 mm of glass (Nikon Instruments, Inc., Japan [78] and
Slidebook 6 software, 3i, Inc.). A pixel dwell time of 2 µs was used with pixel averaging
(5/scan) to acquire three-dimensional (z-stack) images composed of 100 images with a 1
m step size. Baseline images were acquired at least three weeks after lens implantation
and one week prior to the fluid percussion injury procedure. Post-treatment images were
acquired at 1 hour, 3, 7, 14, 30, and 60 days after the procedure. However, between Day
30 and Day 60, most of the animals lost their head plates and as a result, the image sets
were not analyzed at Day 60. Image sets were exported and stored as TIFF files on an
external hard drive for offline analysis.
8.4.5

Fluid Percussion Injury Surgery
To obtain images following a traumatic brain injury in mice, a second surgery was

necessary. The midline fluid percussion injury (mFPI) model surgery [150] was adapted
such that the procedure could be performed after successful GRIN lens implantation and
baseline imaging. To perform mFPI, a craniectomy, was created with the dura intact and
an injury hub was attached. The injury hub facilitates attachment of the animal to the
mFPI device. Once the injury was completed, the hub was removed and the skin was
sutured to cover the craniectomy. The primary change was made during the injury hub
attachment step. Kwik-Sil (World Precision Instruments) was used in place of dental
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cement. This step protects the GRIN lens from being removed when the injury hub was
removed.
The animal was initially anesthetized with 5% isoflurane. Once the animal no
longer exhibited a righting response, it was transferred to a stereotaxic frame equipped
with ear bars and nose cone for anesthesia delivery. The surgical area was cleaned with
91% isopropyl and iodine. Once the area was dry, a 1 mm thick piece of weed whacker
line was glued on the midline between bregma and lambda with liquid cyanoacrylate
(Krazy Glue ®), which served as a guide for a trephine to create a craniectomy.
After the cyanoacrylate dried, trephining began so that a 3 mm craniectomy was
created. Trephining continued until the bone flap was able to move independently of the
skull. Care was taken not to cut into the dura with the trephine. If the dura was
compromised, the animal was removed from the study. The bone flap was removed by
pulling on the piece of weed whacker. If the weed whacker line came off prior to
removal, a pair of fine forceps was used to gently remove the bone flap without piercing
the dura. Once the bone flap was removed, cotton pads and sterile 0.9% saline were used
to control the bleeding. The injury was then prepared.
Injury hubs were constructed using 24 G hypodermic needles. The needle hub
was cut just above the second white line so that the hub opening could fit over the 3 mm
diameter craniectomy. To determine if the hub opening was the proper size, the trephine
was placed in the cut end of the hub to ensure a sufficient opening for the fluid used in
the FPI procedure. The hub was placed over the craniectomy and secured with gel
cyanoacrylate (Loctite ®). Next, Kwik-Sil, (World Precision Instruments, LLC) a
biocompatible, silicone adhesive was used in place of dental cement to secure the injury
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hub to the skull. The Kwik-Sil touched the head plate, but was easily removed following
injury. Kwik-Sil’s elastomer properties cause it to deform more than dental cement when
forces are applied. Consequently, this caused inconsistent degrees of injury in animals in
preliminary studies. To circumvent this challenge, once the Kwik-Sil had cured, dental
cement was placed over the Kwik-Sil to prevent movement of the Kwik-Sil that could
reduce the fluid pressure that reached the brain (Figure 5-5). The dental cement should
only cover the Kwik-Sil and not run onto the head plate or the head plate could
potentially be pulled off during injury hub removal. Once the dental cement was dry, the
hub was filled with 0.9% saline and checked for leaks. Any leaks were sealed before
terminating anesthesia. Once it was determined that there were no leaks, the animal was
removed from anesthesia and transferred to a heating pad until recovered.

Figure 55. Injury hub attachment required the use of both Kwik-Sil, to cover and protect
the GRIN lens, and dental cement, to ensure proper pressure for the FPI procedure.
8.4.6

Fluid Percussion Injury
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Animals were randomly divided into either sham (n=4) or FPI (n=14). Each
animal was anesthetized with 5% isoflurane for 5 minutes in an anesthesia chamber.
Immediately after removal from the chamber, the injury hub was filled with 0.9% saline
and connected to the fluid percussion injury device (Custom Design & Fabrication,
Virginia Commonwealth University, Richmond, VA) (Figure 56A). The device causes
injury by applying a brief fluid pressure pulse to an intact area of dura. The pulse was
created by a heavy hammer (Figure 56B) head on a swinging pendulum (Figure 56C)
that strikes a fluid filled cylinder (Figure 56D). This caused a brief compression of the
brain (<20 ms). The animal was checked with toe pinches and when a response was
exhibited, but before the animal had fully regained consciousness, the pendulum was
released [150]. After impact, the animal was detached from the device and placed on a
heating pad until the animal righted itself (Braintree Scientific, INC.). The elapsed time
from injury to the righting response was recorded. For a moderate injury, a righting
response between 6-10 minutes was needed. For sham injured animals, the same
procedure was followed except, the pendulum was not allowed to hit the fluid filled
cylinder. After the animal had righted itself and the parameters of injury were recorded,
and the animal was returned to its home cage.
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Figure 56. Fluid percussion injury device. The animal is connected to the device via tube
with a leur lock ending (A) and a hammer head (B) on a pendulum (C) hits the fluid filled
cylinder (D) which causes a brief pressure pulse (< 20 ms) onto the intact dura of the
mouse brain.
To seal the craniectomy after injury, the animal was briefly anesthetized for five
minutes and then transferred to a frame equipped with ear bars and a nose cone.
Anesthesia was maintained at 1.5% for the duration of craniectomy sealing. Sterile saline
was used to clean the area before sealing. After the area was sterile, 1.5% low melt
agarose (IBI Scientific, Peosta, Iowa) was placed on the craniectomy followed by a #1.5
cover glass, 3 mm in diameter (Electron Microscopy Sciences, Hatfield, Pennsylvania,
USA). Once the agarose had solidified, gel control cyanoacrylate (Loctite®) was
carefully placed around the edges of the cover glass. Care was taken to not allow the
cyanoacrylate to run under the cover glass and agarose and onto the dura mater. Once the
cyanoacrylate had cured (about five minutes), Aplicap™ (RelyX ™ Unicem) was placed
on the skull, beginning on the edges of the cover glass until it had completely covered
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any openings to the skull. Aplicap™ was allowed to cure for at least 20 minutes before
transferring the animal to the TRIO system[15] for the one hour imaging time point.
8.4.7

Minocycline Administration
Animals were randomly divided into four groups as follows: sham injury with

saline treatment (sham-vehicle), TBI with saline treatment (TBI-vehicle), TBI with
minocycline treatment beginning at 45 min (TBI-45-min), and TBI with minocycline
treatment commencing at 72 hr post TBI (TBI-72-hr). Minocycline (45 mg/kg) (Tocris
Bioscience) or 0.9% saline was administered intraperitoneally three times for each group,
the initial dose, and then another at 24 hours and 48 hours after the first dose.
8.4.8

Acute Behavioral Evaluations
To determine if acute cognitive and sensorimotor deficits are present following

fluid percussion injury, the rotarod and neurological severity score (NSS) were evaluated
at Days 2, 5, and 7 [151].
8.4.8.1

Rotarod score
The Accurotor Rotarod (AccuScan Instruments, Inc. Columbus, Ohio USA) was

used to assess sensorimotor functions. Animals were acclimated to the device three days
before injury (acclimation period). The animal was placed on the stationary rod and
allowed to explore the rod for 30 seconds. If the animal fell off the rod before the 30
seconds, the animal was placed back on the rod. Once the animal had successfully
explored the stationary rod for 30 seconds, the angular frequency of the rotarod was
adjusted to a constant rate of five revolutions per minute (rpm). If the mouse fell off the
rod, it was placed back on the rod and the timer restarted until it could walk for 15
seconds. After this, the rotarod speed was adjusted to an acceleration of 0.2 rpm/s. The
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trial ended once the animal fell off the rod. The animal was returned to its cage for 10
minutes and the accelerating rod portion of the test was re-run. Again, once the animal
fell, the animal was returned to its home cage, and the acclimation phase ended.
The testing procedure began three days before injury and was run on Days 3, 2,
and 1 before injury. The procedure took place at the same time each day, between four
and seven pm, to minimize any variability. The mice were placed on the apparatus and
were tested for their ability to remain on the rotarod with an acceleration of 0.2 rpm/s.
The apparatus is equipped with sensors to detect when the animal falls and records the
time in seconds. Three trials were run on each testing day, with trial one and two run
back to back and the third trial run after a 10 minute break. The two best times were
averaged for the day. The average time for one day before injury was used as the baseline
data point. The rotarod test was used on Days 2, 5, and 7 following FPI to detect if motor
deficits were present.
8.4.8.2

Neurological severity score
To evaluate neurological impairment following FPI, eight behavioral tests were

performed. The tests determined the function of the cortex and cerebellum, and if any
additional motor deficits were present. The mice were assessed on the presence of 1) hind
limb flexion, 2) seeking behavior, 3) startle response, ability to walk across 30 cm long,
square cross section, beams with progressively smaller widths of (4) 3 cm, (5) 2 cm, and
(6) 1 cm width, and to (7) balance on a 0.5 cm square beam and a (8) 0.5 cm rod with a
circular cross section. Each of these 8 tasks was scored either as a one for failure or zero
for success. The sum of the scores was the Neurological Severity Score (NSS). These
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tests were conducted on Days 2, 5, and 7 following injury. Data are presented as a score
ranging from zero to eight, with a high score indicative of impairment.
8.4.9

Long Term Behavioral Evaluations
To determine the presence of long term deficits following fluid percussion injury

and minocycline administration, behavioral function was evaluated at 60 days post-FPI.
The open field, novel object recognition, and tail suspension were used to assess anxiety,
memory, and depression, respectively. Evaluations were recorded and evaluated offline
by observers who were blinded to treatment conditions. Animals were acclimated to the
testing environment 30 minutes prior to testing. The open field, novel object recognition
and tail suspension test were run serially. Open field and novel object recognition tests
were run in a 30 cm3 arena painted white and marked with 16 square crossings [152].
8.4.10

Open Field Test
The open field test evaluates locomotor and anxiety like behavior. Mice

inherently will avoid brightly lit areas, but also have an innate drive to explore for
perceived threats. When these two drives conflict, the result is anxiety. If anxiety
increased, the mouse would have had increased preference toward the edges of the box
and would have decreased locomotor activity.
To begin the test, the animal was placed in the middle of the empty arena and
allowed to explore for five minutes. The movement was tracked by an overheard camera
and analyzed offline. The distance traveled, time spent in the center of the arena, and
number of entries into the center was recorded.
8.4.11

Novel Object Recognition
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Two identical objects are placed in opposing corners of the arena. Animals were
placed in the center of the arena with their snouts opposing the objects. Animals were
allowed to explore the objects for five minutes and then they were returned to their home
cages. One of the objects was removed and a novel object was put in its place. The
animals were placed in the arena and allowed to explore for five minutes before returning
them to their home cages. The task was recorded by an overhead camera and the amount
of time spent with the objects was recorded by blind observers. If no memory impairment
was present, the animals spent more time with the novel object.
8.4.12

Tail Suspension
The animal is hung by its tail, taped to a beam approximately 20 cm from the

ground for six minutes. During this time, the animal will attempt to escape and reach for
the ground. The task was recorded by a camera and the time it takes for the animal to
become immobile was calculated offline by blind observers. If depressive like symptoms
were present, the animal spent less time attempting to escape.
8.4.13

Animal Perfusions
Within 1 – 3 hours following Day 60 imaging, mice were deeply anesthetized

with an intraperitoneal injection of a ketamine (10 mg/kg)/xylazine (1 mg/kg) solution.
After deep anesthesia was confirmed with noxious toe pinches, mice were transcardially
perfused first with phosphate buffered saline (PBS) until blood was cleared, and then
with 20 mL of cold (4 °C), 4% paraformaldehyde solution, 7.2 pH (PFA) [14]. Heads
were decapitated and then post-fixed in PFA overnight. Next, lenses were removed from
the brain and the brains were removed from the skull [14]. After removal, brains were
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immersed in PBS with 30% sucrose in preparation for future cryosectioning and antibody
staining.
8.4.14

Image Analysis
Exported 16-bit TIFF files were analyzed in ImageJ (version 1.51i) software

(NIH). Each stack for each time point was realigned using "StackReg", a downloadable
plug-in, to correct minor misalignment of successive images caused by motion
artifacts[153]. After correcting image alignment, an average intensity z projection of 11
successive images acquired in 1 µm z steps was created for each time point. An identical
field of view was chosen for each time point to track the same axons over time.
The percent of axons with undulations, varicosities, and terminal bulbs was
determined at each time point. Individuals blind to the treatment groups, compared
images at the post-injury time points to baseline. Observers used the drawing and region
of interest (ROI) tools in ImageJ (version 1.51i) to indicate which axons had the features
of damage by drawing a box around the axon and naming it U, V, or T, if the axon
exhibited an undulation, varicosities, or a terminal bulb, respectively. Only the damaged
axons were counted and not the number of features (i.e., not each swelling) present on the
axon since the entire axon may not be in the entire field of view. The ROIs were saved at
each time point and uploaded to a Google Drive. The ROIs were tabulated at each time
point for each animal in Microsoft ® Excel. Data were presented as the mean ± SEM
percentage of axons with each feature at each time point in each treatment group. Data
were transferred to GraphPad Prism for statistical analysis.
8.4.15

Progressive Axonal Damage
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To demonstrate progressive axonal injury, individual axons were tracked over
time. If an axon demonstrated varicosities or an axonal bulb in the baseline image, the
damaged axon was excluded from future analysis (approximately one axon per animal
had either varicosities or was a terminal bulb in baseline). Undulated axons at the onehour time point were followed over the course of the experiment and their outcome was
recorded as either developing into a varicosity or returning to its baseline state. The
percent of undulated axons developing into varicosities or recovering was determined.
Axons with varicosities were tracked over time and at the end of the 30-day time period
were identified as 1) developed into a terminal bulb or lost axon, 2) recovered (no sign of
injury), or 3) unrecovered (varicosities remained). The time point at which the axons
exhibited these traits was recorded. The percent of axons developing into a terminal bulb,
recovering, or being unrecovered was determined. Additionally, the percent of
varicosities was determined at each time point. Data were recorded in Microsoft ® Excel
and then transferred to GraphPad Prism for statistical analysis.
8.4.16

Statistical Analysis
Data were expressed as a mean ± SEM of n, where n represents the number of

animals used. The data collected was analyzed with GraphPad Prism software. A oneway ANOVA was used to compare mean results. A Bonferri post hoc test was used to
adjust for multiple comparisons and statistical significance was defined as p < 0.05.
8.5
8.5.1

Results

Injury Severity
Animals were either subjected to moderate fluid percussion injury (n=14) or sham

injury (n=4), in which the animals undergo the same procedures as the injured group
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except the hammer on the device was not allowed to hit the piston. An injury was
classified as moderate if the righting time between 6-10 minutes. Figure 57 represents
the mean righting time in each experimental group (TBI-vehicle, n = 5, TBI-45-min
minocycline, n =4, TBI-72-hr minocycline, n =5).

Figure 5-7. Average righting times (s) for each group. All injured groups were subjected
to moderate fluid percussion injury. Data is represented a mean ± SEM.
8.5.2

Neurological Severity Score
To assess acute neurological deficits post-injury, a neurological severity score

(NSS) was given on Days 2, 5, and 7 post injury by a blinded assessor. On Day 2, as
expected, all injured groups, regardless of treatment, had significantly higher NSS than
the sham-vehicle treated group. On Days 5 and 7, the TBI-45-min minocycline treated
group was not significantly different from the sham-vehicle group. On Day 7, the TBI72-hr treated minocycline group was not significantly different from the sham-vehicle
group. Both treated groups showed signs of neurological recovery by Day 7.
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Figure 56. NSS tests results. The TBI-45-min minocycline treated group recovered by
Day 5, as it was no longer significantly different than sham-vehicle. At day 7, TBI-72-hr
minocycline treated animals were not significantly different than sham-vehicle. The TBIvehicle treated animals had significant neurological deficits for the first week following
injury. Data is represented as mean ± SEM. *p < 0.05 vs. sham-vehicle at the same time
point
8.5.3

Rotarod Performance Test
Acute motor deficits were measured on Days 2, 5, and 7 immediately following

the NSS assessment. Latency to fall was normalized with baseline values to account for
variabilities between animals. The TBI-vehicle treated and TBI-72-hr minocycline treated
group had the expected motor deficits as compared to the sham-vehicle treated mice
(Figure 57). The TBI-45-min minocycline treated group did not have significant motor
deficits at Day 2 and performed even better than the sham-vehicle treated group by Day
5. At Day 5, while the TBI-vehicle treated and TBI-72-hr minocycline treated group did
not perform significantly worse than the sham-vehicle animals, they still exhibited motor
deficits as compared to sham-vehicle.
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Figure 57. Latency to fall times were normalized with baseline to reduce inter-animal
variability. The TBI-45 minute minocycline treated group did not have motor deficits at
any time point. Both TBI-vehicle and TBI-72-hr minocycline treated animals had
significant motor deficits at Day 2 and continued to exhibit deficits at Day 5 and Day 7 as
compared to sham-vehicle treated animals. Data represented as mean ± SEM. * p < 0.05
vs sham-vehicle at each time point
8.5.4

Evidence of Undulated Axons In Vivo
Undulations are caused by rapid compression and elongation of axons when the

brain is subjected to accelerative forces, causing breaks in the microtubules. Undulations
were apparent at the 1 hour time point (Figure 58B). Some undulations persisted on Days
3 and 7 but by Day 14, no axons were undulated (Figure 58A). Since undulations are a
property of mechanical damage, minocycline was not expected to prevent the
development of this feature. The groups were not significantly different. While all FPI
groups exhibited, on average, more undulated axons following injury than the sham
injured group, some animals did not have undulated axons, but already began exhibiting
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varicosities. The identification of undulations confirms the in vitro and in silico work
done by others [141], [142], [148].

Figure 58. Undulations result from mechanical stretching and elongation of axons. All
injured groups exhibited more undulations than the sham injured group (A). Some
undulations persisted until Day 7, but by Day 14, no undulations were apparent in any of
the injured groups. Representative images of undulated axons (white arrows) persisting
until day 3 (B). Each image is a z projection of 11 x 1 µm slices. Scale bar = 10 µm.
8.5.5

Varicosities Persist Through 30 Days
Following diffuse axonal injury, varicosities are caused by damaged microtubules

and interrupted axonal transport. Axons with varicosities are identified by the presence of
periodic swellings (Figure 59B, white arrows). Additionally, secondary injuries, such
as calcium overloads, cause microtubules to break down, leading to the development of
additional varicosities. Beginning at one hour, all groups undergoing injury developed
varicosities, independent of treatment. At Day 3, while both the TBI-vehicle and TBI-72hr minocycline treated group had significantly more varicosities than the sham-vehicle
treated group (p = 0.0195 and p = 0.0095, respectively), the TBI-45-min minocycline
treated group was not significantly different than the sham-vehicle group (Figure 5-9,
Day 3). Furthermore, while both the TBI-vehicle and TBI-72-hr minocycline treated
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animals had an increase in the percent of axons with varicosities at Day 3 as compared to
1 hour, the TBI-45-min minocycline treated animal had little change. Throughout all time
points, the TBI-vehicle treated group exhibited a higher percentage of varicosities with a
progressive increase until Day 7, at which point the percent of varicosities begins to
decrease, but the percent of axons with varicosities remains higher than the TBI-72-hr
minocycline treated or sham-vehicle groups (p = 0.07 and 0.003, respectively) at Day 14
(Figure 59A, Day 14). At Day 7, the TBI-45-min minocycline treated group had
significantly fewer varicosities than the TBI-vehicle treated group (p = 0.016) (Figure 59A, Day 7). When minocycline is administered at 72 hours, the average percent of axons
with varicosities shows a decrease at Day 7. By Day 14, while it is not significantly
different than the TBI-vehicle treated group, the p-value was 0.07, which demonstrates a
nonsignificant trend (Figure 5-9A, Day 14). Axons in both minocycline treated groups
exhibited less damage as compared to the TBI-vehicle treated group.
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Figure 59. Varicosities develop due to interrupted axonal transport after injury (white
arrows) (B). The TBI-vehicle treated group developed more varicosities over time versus
the sham injured and minocycline treated groups. When minocycline is administered
beginning at 45 minutes, it exhibits a protective effect by preventing development of
varicosities during the first week and is not significantly different than the sham-vehicle
at any time point. Administering minocycline beginning at 72 hours also protects against
the development of future varicosities, apparent at day 14 (p = 0.07 versus TBI-vehicle)
(A). * p < 0.05 (versus sham-vehicle), # p <0.05 (versus TBI-vehicle). Each image is a z
projection of 11 x 1 µm slices. Scale bar = 10 µm (B).
8.5.6

Terminal Bulbs and Axon Loss
Persistent varicosities can cause the axon to become weak and eventually lead to

disconnection and axon loss. When this occurs, the proximal end of the axon retracts
toward the cell body, characterized by a large area of swelling at the end of the axon
(Figure 510C-E). In this study, terminal bulbs were not counted as axon loss until the
terminal bulb was entirely out of the field of view. Additionally, due to the nature of
diffuse injury, axon loss would appear to occur without the development of a terminal
bulb. The point of disconnection was most likely at a site outside the field of view or
terminal bulb development occurred but was not imaged at the time point.
Over time, as expected, the TBI-vehicle treated group had the most terminal bulbs
and/or axon loss. While not statistically significant, the TBI-45-min minocycline treated
group showed no terminal bulbs or axon loss until Day 14 and Day 30, respectively. In
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fact, the TBI-45-min treated group had fewer axonal bulb developments over time than
even the sham-vehicle treated group. The TBI-72-hr minocycline treated group had an
increase in axonal bulb development and axon loss at Day 14, with this trend persisting
until Day 30 (Figure 510A, B).

Figure 510. Terminal bulbs develop when an axon disconnects, eventually leading to
axon loss. (A, B) TBI-vehicle treated had the most persistent axonal bulbs and axonal
loss overtime. The TBI-45-min treated minocycline group had few terminal bulbs and
minimal axonal loss, with no development until day 14. (C-E) Representative images of
terminal bulbs (white arrows). Each image is a z projection of 11 x 1 µm slices. Scale
bar = 10 µm.
8.5.7

Progressive Axonal Damage
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While identifying features at each time point offers information about the total
damage occurring post-injury, it does not demonstrate how the damage progresses. Since
minocycline is not administered until after the primary mechanical damage occurs, it
does not protect against the development of undulations (Figure 58A) and early
varicosities (Figure 59A, 1 hr). However, when administered in a short window after
injury, it was shown to protect the white matter regions of the brain long term [92]. With
this novel imaging system, it was possible to track individual axons over time. As a
result, a better understanding about the progression of diffuse axonal injury and how and
when minocycline exhibits a protective effect was discovered. Damaged axons were
tracked over time to determine axon fate. Undulations either developed into varicosities
or recovered back to their baseline state. Varicosities, over time, recovered, developed
into terminal bulbs, or persisted until the Day 30 time point. The data represented in
Figure 58Figures 5-8, 5-9, and 5-10 were further investigated to determine the time
course of injury and minocycline protection.
8.5.8

Undulations
Undulations occur at the moment of injury, and because they involve breaks in

microtubules and neurofilaments, they can lead to varicosities (Figure 511A). They can
also recover back to their baseline state (Figure 511B). Since undulations are a direct
result of the mechanical forces applied to the brain during injury, minocycline
administration protected against the development of these features. However, in vitro and
in silico research has demonstrated undulations develop into varicosities after dynamic
stretch injury [141], [142], [148]. This study confirms this mechanical damage in vivo as
the majority of identified undulated axons developed into varicosities (Table 5-1).
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Table 51. Undulated axons develop into varicosities. The undulated axons were tracked
to determine if they developed into varicosities or recovered. The percent of undulated
axons developing into varicosities was calculated. Data is represented as mean ± SEM.
Treatment Group

Undulated Axons (%)

Sham-vehicle
TBI- vehicle
TBI- 45 min
TBI- 72 hour

0.9 ± 0.9
9.2 ± 2.1
11.1 ± 5.3
11.9 ± 2.4

Undulated Axons to
varicosities (%)
0±0
70 ± 20
100
86.7 ± 13.3

Figure 511. Undulated axons can been seen at 1 hour (white arrows) and A) develop
into varicosities (white arrows) or B) recover over time (white arrows). Each image is a
z projection of 11 x 1 µm slices. A) Scale bar = 5 µm, B) Scale bar = 10 µm.
8.5.9

Minocycline Mitigates Progressive Damage
The novel imaging system was used to measure the varicosities’ fate over 30 days

following TBI to determine the long-term protective properties of minocycline. The
average percent of total axons developing varicosities was measured for each treatment
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group. The varicosities were tracked and identified as 1) developing into a terminal bulb
or resulting in axon loss, 2) recovering back to baseline state (Figure 512, solid white
arrow), or remaining unresolved (Figure 512, white dashed arrow) during the 30 day
time period.

Figure 512. Representative images demonstrating the difference in recovered varicosities
(solid, white arrow) or unresolved varicosities (dashed, white arrow). Each image is a z
projection of 11 x 1 µm slices from identical field of views. Scale bar = 10 µm.
As expected, the sham-vehicle treated group had significantly fewer varicosities
develop over the 30 day time period as compared to TBI-sham treated (p = 0.0009) and
TBI-72-hr minocycline treated (p = 0.015) groups (Table 5-2), since early damage could
not be prevented. The TBI-45-min minocycline treated group had fewer varicosities
develop than the TBI-vehicle group (p = 0.056). While the injured groups had more
varicosities develop overall than the sham-vehicle treated group, the fate of the axons at
Day 30 varied. The TBI-45-min minocycline treated group had less than half (47 ± 20 %)
of the axons resolve, while the others remained unresolved (53 ± 20 %) at the 30 day time
point. Since this number was similar to the TBI-vehicle treated group (46 ± 6), the
percent of varicosities developing into terminal bulbs was considered. The TBI-45-min
minocycline-treated group had no tracked varicosities develop into terminal bulbs, while
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the TBI-vehicle group had approximately a quarter (27 ± 7 %) develop into terminal
bulbs.
Table 52. Individual axons with varicosities were tracked over 30 days and their fate was
assigned as recovered, unresolved, or resulting in a terminal bulb or axon loss for each
treatment group. Data is represented as mean ± SEM. * p< 0.05 (vs. sham-vehicle), # p <
0.05 (vs. TBI-vehicle)

Treatment
Group

Sham-vehicle
TBI-vehicle
TBI- 45-min
TBI- 72-hr

Varicosities
formed
(%)

Recovered
varicosities
(%)

Unresolved
varicosities
(%)

Varicosities
resulting in
terminal bulbs
or axon loss
(%)

13.2 ± 1.1
58.5 ± 6.3*
35.1 ± 6.6
( p = 0.056 vs
TBI-sham)

62.5 ± 14.2
45.8 ± 5.9

29.2 ± 10.5
30.45 ± 8

8.3 ± 8.3
27 ± 6.7

46.9 ± 21.9

53.1 ± 21.9

0±0#

46 ± 4.3*

69.2 ± 8.3

22.5 ± 6.7

5±5
(p = 0.09, vs
TBI-sham)

However, while none of the tracked axons developed into terminal bulbs in the
TBI-45-min minocycline treated group, terminal bulbs and axon loss were present (Table
53), albeit significantly less than the TBI-vehicle group (p = 0.027). Occasionally,
terminal bulbs and axon loss were identified without the presence of varicosities. Because
the injury was diffuse, the axon could have had varicosities outside of the field of view
(Figure 5-13).

Table 53. Average percent of total axons resulting in terminal bulbs or axon loss.
Data is represented as mean ± SEM. * p < 0.05 (vs. sham-vehicle), # p < 0.05 (vs. TBIvehicle)
Treatment
Group

Terminal Bulb and Axon Loss
(%)
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Sham-vehicle
TBI-vehicle
TBI-45 minute
TBI-72 hour

3.1 ± 1.4
25.3 ± 0.9 *
5.9 ± 4.7 #
±
9.2 5.3 (p = 0.09 vs TBI-sham)

Figure 513. Representative image of axon disappearing (white arrow) without the
formation of varicosities. It is possible the axon was damaged in an area outside the field
of view or the development of a terminal bulb was not identified at the imaging time
point. Each image is a z projection of 11 x 1 µm slices. Scale bar = 10 µm.
While minocycline may not resolve all varicosities, it protects damaged axons
from developing into terminal bulbs and consequently, leading to axon loss (Table 5-3).
The TBI72hr minocycline treated group had nearly 70% of the varicosities recover and a
low percentage of tracked varicosities developed into terminal bulbs (5 ± 5 %, p = 0.09
vs. TBI-vehicle) (Table 52). Furthermore, the TBI-72-hr minocycline-treated group had
overall fewer terminal bulbs than the TBI-vehicle treated group (p = 0.09) (Table 53).
This demonstrates by extending the therapeutic window out to 72 hours, axons are
protected from loss, and minocycline may be creating an environment where axons are
able to recover.
8.5.10

Development of New Varicosities
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Varicosities are apparent when mice are imaged at one hour and persist for the 30
day timeframe (Figure 514, white arrowheads). Some varicosities are present in the
baseline, but these axons were not included in future analysis (Figure 514 A, G, M, and
S). Furthermore, varicosities can develop due to secondary injuries and are not apparent
until later time points (Figure 514, white arrowheads). To further investigate if the
varicosities persisted over time or if new varicosities were contributing to the overall
measurements at each time point, individual axons were tracked to determine the time
point at which they developed varicosities.
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Figure 514. Representative images demonstrating progressive axonal damage for each of
the treatment groups. Overall, less damage is apparent in the sham-sham (A-F) and
groups treated with minocycline at 45 minute (M-R) and 72 hours (S-X). Individual
axons with varicosities (white arrow heads) could be tracked over time to determine
their fate and time point at which they appear and recover. Scale bar = 10 µm.
When minocycline is administered at 45 minutes, no difference is found in the
total percent of undulations or percent of varicosities at the one hour time point, as
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compared to the other injured groups (Figure 58A & Figure 59A). The protective effect
of minocycline administration beginning at 45 minutes is not seen until Day 7 when the
average percent of varicosities is significantly lower than TBI-vehicle (p = 0.016), and
only 12.5 ± 12.5 % of those are new varicosities (Table 54). At Day 3, the TBI-72-hr
minocycline treated group began their treatment. The average percent of varicosities at
Day 3 is not significantly different than the TBI-sham treated group (p > 0.99) (Figure
59A). However, at Day 14, the TBI-72-hour minocycline treated group, had a lower
average percent of axons with varicosities than the TBI-vehicle treated group (p = 0.07)
(Figure 55A), with 30 ± 20% of the varicosities being new (Table 54). At this time
point, TBI-vehicle had the fewest new varicosities developing (18 ± 5 %) (Table 54), but
also had the highest percent of terminal bulbs and axon loss (Figure 58A) up until this
time point, signifying that a great deal of damage had already occurred.
Table 54. Development of new varicosities over time. The average percent of axons
with new varicosities at each time point was measured. Data are represented as mean ±
SEM.
Treatment
Group
TBI-vehicle

1 hr (%)
100

TBI- 45 min

100

TBI-72 hr

100

Day 3
(%)
59 ± 14
46
± 21
52 ± 17

Day 7 (%)

Day 14 (%)

Day 30 (%)

24 ± 10

18 ± 5

30 ± 21

13 ± 13

25 ± 14

0.0 ± 0.0

37 ± 16

30 ± 20

0.0 ± 0.0

Taken together, minocycline does not have an immediate protective effect, but
takes time to intervene in the progression of axonal damage. Additionally, by
administering minocycline beginning at both 45 minutes and 72 hours, while the time
course of protection is different, no new varicosities develop at 30 days (Table 54).
Additionally, the development of terminal bulbs or axonal loss from identified
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varicosities is decreased (Table 52) and overall the two treated groups had fewer terminal
bulbs develop than the TBI-vehicle treated group (Table 53). As a result, while
minocycline cannot protect against the initial mechanical injury, it has a long term role in
mitigating further damage and preventing axon loss.
8.5.11

Late Behavioral Outcomes
Three behavioral tests were used on Day 60 to determine if minocycline protected

late behavioral outcomes: open field, novel object recognition, and tail suspension test.
The open field test was used to measure anxiety like behavior. If animals’ spent more
time in the periphery of the arena, anxiety like behavior was present. The novel object
recognition test was used to determine if memory deficits were present. If an animal
spent an equal amount of time with familiar and novel objects, they were not able to
discern between the two objects and memory deficits were present. The tail suspension
test was used to measure depressive like behavior. If animals spent less time actively
attempting to escape while being suspended by their tails, depressive like behaviors were
present.
In the open field test, there was no statistical difference between injured and
uninjured groups. All animals spent a comparable amount of time in the peripheral zones
of the arena, independent of treatment (Figure 5-15).
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Figure 515. No statistical significant difference was measured between injured and
uninjured groups. All animals spent comparable time in the peripheral zones of the arena.
In the tail suspension test, no statistical difference was found between groups.
However, the TBI-45-min minocycline treated group and TBI-vehicle treated group spent
the least amount of time actively seeking escape, while the TBI-72-hr minocycline
treated group spent the most amount of time actively seeking escape.
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Figure 516. There was no statistical difference between injured or uninjured groups in
the tail suspension test. However, it appears the TBI-72 hr minocycline treated group
spent the most time actively attempting to escape.
In the novel object recognition test, sham-vehicle treated animals spent
significantly more time with the novel object than the familiar object (p = 0.016), which
is expected. The TBI-vehicle treated animals were not able to discern between the
familiar and novel object (p = 0.946), indicating a memory deficit is present long term
following TBI. When minocycline was administered 45 minutes following TBI, memory
impairment was protected as the TBI-45-min minocycline treated group spent
significantly more time (p = 0.045) with the novel object than the familiar object. While
the administration of minocycline at 72 hours post TBI appears to be protective against
axonal degeneration, it did not protect against memory impairment as the TBI-72-hr
treated animals appear to spend more time with the familiar object, indicating memory
impairment is present (Figure 5-17).

Figure 517. Novel object recognition scores indicate that the TBI-vehicle and TBI-72-hr
minocycline treated animals were unable to discern between familiar and novel objects,
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indicating a memory deficit is present. Both the sham-vehicle and TBI-45-min
minocycline treated spent significantly more time with the novel objects as compared to
the familiar objects, indicating administration of minocycline at 45 minutes post TBI is
protective against the development of memory deficits. * p < 0.05 vs. familiar object
8.6

Discussion and Conclusion

Diffuse axonal injury, while resulting in wide spread damage, primarily affects
the corpus callosum, a region deep within the brain. Rapid compression and elongation of
the tissue causes small breaks in the microtubules and neurofilaments that cause axons to
become undulated. These small breaks disrupt the transport of axonal proteins, resulting
in periodic swellings, called varicosities. The varicosities weaken the axon and can
eventually lead to terminal bulbs and ultimately axon loss. To date, the research
conducted about the progression of these features has been limited to in vitro, in silico,
and histological studies [7], [36], [141], [142], [144], [148], [154]. While these
techniques are essential, no data were collected in vivo to confirm these results, until
now. For the first time, the research conducted in this longitudinal study confirms that the
forces from traumatic brain injury cause undulations, which lead to varicosities, and
ultimately result in terminal bulbs and axonal loss.
Traumatic brain injury affects a large amount of the population, and as result it is
imperative the scientific community discovers therapeutic interventions to diminish the
progression of this injury. Minocycline, an FDA approved antibiotic with antiinflammatory properties when given in high doses, has shown promise in mitigating
damage from diffuse axonal injury [87], [153], [92], [154], [155], [91], [94]. While this
drug has shown promise in protecting the white matter in the brain when given in a short
time frame after injury [16], how and when the drug is contributing to this protection is
still unknown. Additionally, it is not always possible to treat individuals immediately
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following injury. Therefore, it is necessary to investigate if minocycline exhibits
protective effects when administered in a longer therapeutic window. Contributing to this
research, the novel longitudinal imaging system used in this study demonstrated both the
short and long term effects of the drug and established that administering minocycline at
72 hours after injury has protective properties.
When minocycline is first administered 45 minutes after injury, the effect is not
immediate, with no statistical difference measured in the percent of varicosities at the one
hour time point (Figure 59A). However, the total axon damage is mitigated long term.
This mitigation is seen as a smaller percent of axons developing varicosities overall (p =
0.056, vs TBI-vehicle) (Table 52). In fact at Day 7, the TBI-45-min treated group had
significantly fewer varicosities than the TBI-vehicle treated group (p = 0.016).
Additionally, while some varicosities persisted during the 30 day time frame of the
experiment, no new varicosities were present at Day 30 (Table 54) and significantly
fewer axons resulted in terminal bulbs or axons loss as compared to the TBI-vehicle
treated group (p = 0.027) (Table 53).
The results of the study demonstrated that administering minocycline at 72 hours
may be beneficial. Again, when minocycline is first administered, the result is not
immediate, and a difference in the percent of varicosities is not seen until Day 14 when
compared to the TBI-vehicle treated group (p = 0.07) (Figure 59A). Furthermore, 70% of
the varicosities that developed recovered by ay 30, which was more than both the
TBI45min minocycline-treated group (47%) and the TBI-vehicle treated group (46%)
(Table 52). Similar to the TBI-45-min treated group, the TBI-72-hr treated group had no
new varicosities develop at Day 30 (Table 54). Additionally, the total terminal bulb
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development and axonal loss was less than the TBI-vehicle treated group (p = 0.095)
(Table 53). These data demonstrate that this longer therapeutic window not only protects
from axon loss, but also creates an environment in which the axons can recover.
Microglia have a key role in the injury cascade following TBI. After injury,
microglia become chronically activated [154], [158] and microglia DNA was found in
white matter regions months after injury in both rats and humans [38]. Minocycline,
given its anti-inflammatory properties, was shown to mitigate microglia activation
following TBI [87], [92], [159]. As a result, the regulation of microglia through
minocycline may be contributing to the protection of axons. While axons develop
varicosities, they are still functional and in some cases, as shown in this study, recover
back to their baseline state. Activated microglia, in order to maintain homeostasis, will
phagocytose damaged material in the brain. However, in this case, creating an
environment in which microglia are not activated may allow for axons to recover from
the varicosities and prevent terminal bulbs from developing.
In late behavioral outcomes, no difference was found in the open field or tail
suspension test, indicating there was no presence of anxiety or depressive like behavior at
60 days post TBI (Figure 5-15 and Figure 5-16). These results are consistent with
another research study, as no anxiety like behaviors were present at 9 weeks post TBI
[93]. However, in the novel object recognition test, the TBI-vehicle and TBI-72-hr
minocycline treated group were unable to discern between the novel and familiar object,
indicating a memory deficit was present at Day 60. In both the sham-vehicle and TBI-45min minocycline treated group, animals spent significantly more time exploring the novel
object as compared to the familiar object. These results suggest administration of
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minocycline at 45 min, but not at 72 hours post TBI, is protective against the
development of memory deficits (Figure 5-17).
In summary, this study demonstrated the use of a novel imaging system for
identifying the progression of diffuse axonal injury in vivo following a fluid percussion
injury model. Varicosities developed from undulated axons, recovered, persisted, or
advanced into terminal bulbs, which is consisted with other research [121], [142], [145],
[148], [160]. Furthermore, this study demonstrated the efficacy of this system in
preclinical trials by confirming that when minocycline is administered at 45 minutes after
injury, it protects the white matter regions of the brain. Finally, this system was used to
determine the effectiveness of expanding the therapeutic window of minocycline
treatment to 72 hours after injury. While administration at this late time point cannot
protect early damage from progressing, it creates an environment which has long term
protective effects. Future studies will include examining the mechanisms of protection,
such as mitigating microglia activation over time, which may be contributing to this
protection.

CHAPTER 9
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CHAPTER 10
IN VIVO DIFFUSION OF PGP
10.1

Poly(lactide-co-glycolide)-Praft-Polyethylenimine

While viral vectors have shown promise as a delivery mechanism for gene
therapies, they cause immune responses and lack specificity. As a result, the scientific
community has moved toward developing nonviral vectors, which can be manufactured
at large scales, decrease off target effects, and reduce the inflammatory response [103].
Poly(lactide-co-glycolide)-praft-polyethylenimine (PgP), a synthetic polymer has
previously shown promise as an efficient vector for stable intracellular delivery of nucleic
acids, while reducing cytotoxicity as compared to the conventional polyetherimide (PEI)
normally used. Additionally, this carrier successfully delivered siRhoA, a gene involved
in cytoskeleton regulation, via a local injection after a rat compression spinal cord injury
model. The treatment increased axonal regeneration and reduced astrogliosis [104].
Based on these results, PgP carrier may be a candidate for delivering treatment to the
brain after diffuse axonal injury, which results in progressive axonal loss.
In order to determine PgP’s potential as a delivery platform in brain injury, its
diffusion capability in a murine brain was investigated in a short, qualitative study. PgP,
loaded with DiR, a lipophilic near infrared fluorescent dye, was locally injected into the
brain (n = 4) and imaged through a cranial window over 72 hours to determine its
diffusion capabilities.
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10.2
10.2.1

Materials and Methods

Preparation of PgP Polyplexes
PgP polyplexes were prepared by Dr. Jeoungsoo Lee’s lab at the Clemson

University Bioengineering Innovation Campus (CUBEInC), as previously described
[103]. Prepared polyplexes, with a molecular weight of 38,168, were sent to Dr. Teresa
Murray’s lab at Louisiana Tech University.
10.2.2

DiR-PgP Injection
A 1 μL sample of DiR-PgP was loaded into a 5 μL Hamilton syringe (Hamilton

Company, Reno, Nevada, USA) and stereotaxically injected through a craniectomy. Mice
were briefly anesthetized with 5% isoflurane and then transferred to a stereotaxic frame
(Stoelting Co., Wood Dale, Illinois, USA) equipped with ear bars, heating pad, and a
nose cone for isoflurane delivery (Leica Biosystems, INC., Buffalo Grove, Illinois,USA).
A SomnoSuite® system (Kent Scientific, Torrington, Connecticut, USA) was used to
control isoflurane delivery. To ensure the animal was fully anesthetized, toe pinches were
performed every 15 minutes. Aseptic surgical techniques were used to make a midline
incision, and a surgical bone scraper was used to remove the periosteum. A micro drill
and 0.5 mm dental burr were used to make a 2 mm craniectomy in the right hemisphere
of the cortex, and the tip of a 28 G hypodermic needle was used at a low angle to the dura
to remove the dura [14], [15].
The 5 μL Hamilton syringe was loaded and adjusted until it is over the
craniectomy. Positioning was chosen based on the location of large blood vessels, as
puncturing these would cause poor imaging quality. The needle was slowly lowered until
it just touched the surface of the brain. The z coordinate was recorded and the needle was
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lowered 350 μm below the surface of the brain. The needle was then backed out 150 μm
so that it was 200 μm below the surface of the brain. This reversal created a small pocket
for the solution once it was injected. DiR-PgP was injected at a rate of 0.2 μl per minute
until 1 μL of DiR-PgP was injected, and 1.2% low melt agarose (IBI Scientific, Peosta,
Iowa) was placed over the craniectomy and covered with a 5 mm diameter coverslip
(Electron Microscopy Sciences, Hatfield, Pennsylvania, USA). Gel cyanoacrylate
(Loctite) was placed around the edges of the coverslip. A custom designed head plate was
3D printed in-house for use with our TRIO platform imaging support system, which is
also 3D printed in-house [15]. The plastic head plate was aligned with the coverslip and
attached with gel cyanoacrylate (Loctite). All parts were secured with dental adhesive
(RelyX, 3M Corp) before imaging the animal.
10.2.3

Tail Vein Injections
Fluorescein (FITC) conjugated to dextran (Life Technologies ©) was used as a

marker for blood plasma. FITC was injected via the tail vein prior to imaging sessions.
On the first day of imaging (1 hour, 3 hour, and 6 hour time points), FITC was only
injected once to minimize the chance of an overdose.
10.2.4

In Vivo Imaging
Mice were briefly anesthetized with 5% isoflurane and then transferred to a TRIO

platform imaging support system, as previously described [15]. Anesthesia was
maintained throughout the imaging session with 1.5% isoflurane. A Chameleon Vision-2
multiphoton laser (80 MHz, Coherent) tuned to 950 nm was used to excite DiR and FITC
fluorescence. Emitted light was filtered through a red and a green fluorescent protein
filter (Brightline® filters, Semrock, Inc). Scanned images were acquired on a custom,
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upright, multiphoton microscope system, equipped with a Pockels cell and GaAsP
detectors (Intelligent Imaging Innovations, Inc., Denver, Colorado, USA), a 4x/0.10 NA
objective (Nikon Instruments, Inc., Japan), a 10x/0.4 NA objective (Leica, Germany), and
Slidebook 6 software (3i, Inc.). A pixel dwell time of 2 µs was used with pixel averaging
(5/scan) to acquire three-dimensional (z-stack) images composed of 176 images with a 2
m step size. Images were acquired at 1 hour, 3 hours, 6 hours, 24 hours, 3 days, and 7
days after initial injection. Image sets were exported and stored as TIFF files on an
external hard drive for offline analysis.
10.2.5

Perfusion and Fixation of Brain Tissue.
Within 1 – 3 hr of post-procedure imaging, mice were deeply anesthetized with an

intraperitoneal injection of a ketamine (10 mg/kg)/xylazine (1 mg/kg) solution. After
confirming deep anesthesia with noxious toe pinches, mice were transcardially perfused
first with phosphate buffered saline (PBS) until blood was cleared and then with 20 mL
of cold (4 °C), 4% paraformaldehyde solution, 7.2 pH (PFA) [14]. Heads were
decapitated and then post-fixed in PFA overnight. [14]. The brain was removed from the
skull and immersed in PBS with 30% sucrose in preparation for future cryosectioning and
antibody staining.
10.2.6

Image Analysis
Image analysis was performed with ImageJ (version 1.51i) software (NIH). Sum

intensity z projections of 11 x 2 µm slices were created for each time point. Background
mean intensity was calculated and subtracted from each image. Brightness and contrast
were adjusted so similar intensity ranges were used across the time points to qualitatively
compare the diffusion of DiR-PgP.

141
10.3

Results

Time course images of DiR-PgP diffusion were first obtained in vivo with a 10x
objective to qualitatively determine if polyplex spread could be visualized over the course
of 72 hours. Beginning at the one hour time point, polyplexes spread from the injection
point and continued to spread outward from the injection site for the entire 72 hour time
period (Figure 61). By 24 hours, DiR-PgP spread over the entire imaging plane.
Additionally, the polyplexes seemed to have an affinity for the blood vasculature (Figure
61F). To determine if the diffusion was more widespread and that the polyplexes were
not confined by vasculature, later images were taken from mice (n=3) with a 4x
objective.

Figure 61. Representative time course images of in vivo diffusion of DiR-PgP with 10x
objective. DiR-PgP spreads outward over the 72 hour time period (A-E). Polyplexes
appear to congregate around the vasculature (F). Each image is a z projection of 11 x 1
µm slices. Scale bars: 100 µm (A-F)
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Visualization with a larger field of view shows DiR-PgP began spreading
outwards from the injection site at the one hour time point and continued to spread until it
completely covered the field of view at 72 hours. Images were pseudo-colored with the
“Jet” look up table in ImageJ (version 1.51i) to better demonstrate the spread of the
polyplexes (Figure 62). These images demonstrate that DiR-PgP can spread over 72
hours and does not become entrapped by structures, such as vasculature.

Figure 62. Representative images of DiR-PgP polyplex spread over a 2 mm in diameter
craniectomy. Images are pseudo colored with the look up table “Jet” in ImageJ. DiR-PgP
spreads outward beginning at 1 hour and continues to spread until it covers the field of
view at 72 hours post injection (A-E). Each image is a z projection of 11 x 1 µm slices.
Scale bar = 250 µm.

10.4

Discussion
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Delivering effective therapies to the brain is a challenging hurdle which must be
overcome, especially in the case of diffuse brain injury, where damage progressively
occurs. This short, qualitative study demonstrates that PgP may be a promising carrier for
drug therapy in the brain. DiR-PgP diffused over 72 hours, indicating it can efficiently
move through the brain. Images were acquired at Day 7, but the damage from the
injection led to poor imaging quality and an inability to draw any conclusions. Because of
this drawback and since the field of view was limited to a 2 mm diameter cranial
window, following the final imaging session, animals were transcardially perfused and
brains were stored for future cryosectioning and antibody staining. These future studies
will demonstrate the spread of the drug over a seven day time period. Additionally, this
study involved a local injection into the brain, which in itself is a penetrating injury. For
use in most cases of traumatic brain injury, which are closed head injuries, a local
injection would not be feasible. As a result, future studies will further evaluate the
potential carrier by systemically injecting the PgP and determining what dose is
necessary to effectively reach the brain. Overall, PgP shows promise as an effective
platform for delivery and when combined with neuroprotective or neurogenic drugs
might mitigate the damage seen in diffuse brain injuries.

CHAPTER 11
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CHAPTER 12
CONCLUSIONS AND FUTURE WORKS
A novel imaging system was created by chronically implanting GRIN lenses and
multiphoton microscopy was used to image brain dynamics before and after two different
brain injury models. Spatiotemporal data was collected related to both stroke and
traumatic brain injury. Additionally, two potential therapeutics were tested, Annexin A1
and minocycline, for stroke and TBI, respectively. The novel imaging system
successfully imaged both the progression of injury and the effects of the tested
therapeutics, demonstrating the ability to use this tool in preclinical trials.
In a model of ischemia/reperfusion, GRIN lenses, were used to image microglia
activation before and 24 hours following reperfusion injury. The tool successfully
measured microglia activation in subcortical regions of the brain following injury, an area
of the brain not previously studied. Furthermore, Annexin A1 was previously shown to
modulate the inflammatory response following reperfusion injury and does so through the
FPR2/ALX mechanism of action [96], [98]. While the small number of animals was not
sufficient to provide statistically significant results, the in vivo data suggest that Annexin
A1 has the potential to modulate microglia activation in subcortical regions of the brain,
but may not do so through this mechanism of action. Furthermore, post mortem analysis
with brain slices, while not significant, demonstrated Annexin A1 is effective in
protecting the cortex, but not the hippocampus. The novel imaging method used in this
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study was able to collect quality images of microglia and it showed results consistent
with the brain slice analysis. These results demonstrate the effectiveness of this tool for
monitoring microglial activation in a MCAo model and its potential to assess
therapeutics.
The same imaging system used to study microglia activation following a model of
MCAo was adapted and employed in a model of traumatic brain injury. GRIN lenses
were implanted, animals were baseline imaged, and a second surgery was conducted to
carry out fluid percussion injury (FPI). In order to use this model, the FPI surgery had to
be adapted in order to protect the GRIN lens. Kwik-Sil, a silicone elastomer, was used in
place of dental cement to adhere the injury hub to the skull. This elastomer prevented the
GRIN lenses from being pulled out upon removal of the injury hub. The research
conducted successfully carried out FPI while the GRIN lens was implanted. Spatiotemporal data were collected in the external capsule of Thy1-YFP mice over the course of
30 days. The study had several exciting outcomes, which filled several gaps in
knowledge. The novel imaging system, for the first time, confirmed in vivo features of
diffuse axonal injury that were previously studied in vitro, in silico, and with histological
analysis. The device was successfully used as a tool in a preclinical trial. Longitudinal
data were collected to further investigate the time course of a known therapeutic.
Minocycline, an FDA approved antibiotic, protects white matter when administered in a
short time window following injury [87], [91]–[93]. In this study, when minocycline was
administered at 45 minutes following injury, fewer varicosities and terminal bulbs
developed as compared to the sham-treated group. Overall, this time point of
administration protected the white matter, which is consistent with other research
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[91]–[93]. The study expanded the minocycline therapeutic window out to 72 hours.
While not as protective as the 45 minute treated animals, the 72 hour window had better
outcomes than the TBI-sham-treated animals. While initial damage could not be
mitigated, fewer varicosities and terminal bulbs developed, and almost 70% of the
damaged varicosities recovered. This recovery demonstrates that minocycline not only
protects against axon loss, but is creating an environment in which repair can occur.
Minocycline has anti-inflammatory properties and was shown to mitigate
microglia inflammation after injury [87], [92]. The study conducted in Chapter 5
demonstrates that the protective effects of minocycline are time dependent, as it does not
have an immediate effect. The same experimental method used in Chapter 5 could be
employed to look at the effect of the drug on microglia. It would be interesting to
determine if minocycline has a long-term effect on microglia activation or if the
protection only occurs while the drug is being administrated. Furthermore, when
microglia activation occurs and how this correlates to axonal damage would reveal how
and when the environment is changing. This would allow for the optimal therapeutic
window to be determined and lead to recovery of the primary mechanical damage.
From the research conducted in Chapter 5, the effect of minocycline is not
immediate, but takes time to exhibit protective properties. As a result, it may be
beneficial to co-administer this drug with another therapy. For instance, the coadministration of minocycline and N-acetylcysteine at one hour after injury, was shown
to preserve the white matter of the brain, and improve spatial learning [161]. Future
studies conducted should examine the effect of combinatorial therapeutics at differing
time points to discover the best outcome.
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Overall, GRIN lens technology has been shown to be effective as a preclinical
research tool. The device can collect quality spatiotemporal data in deep regions of the
brain, an area inaccessible with current imaging modalities. Imaging windows can be
extended out days and even months after injuries occur to identify the time course of
injuries. Furthermore, in drug development, the tool makes it possible to track the effects
while therapeutics are being administered and identify what occurs once a therapeutic is
stopped in the same mouse. This capability not only reduces the inter-animal variability
but minimizes the number of animals needed in a study. This device has potential far
beyond the studies employed here and will aid other scientists in collecting data about
brain dynamics, the progression of brain injuries, and the development of therapeutics.
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